AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsInformation ScienceHealth Care
LeukemiaLeukemia, Myeloid, AcuteLeukemia, Lymphocytic, Chronic, B-CellLeukemia, LymphoidLeukemia, ExperimentalLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia Virus, MurinePrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, T-CellLeukemia, Monocytic, AcuteMoloney murine leukemia virusLeukemia, Hairy CellLeukemia L1210Leukemia, B-CellLeukemia Virus, BovineLeukemia Virus, FelineGene Expression Regulation, LeukemicLeukemia, Radiation-InducedMyeloid-Lymphoid Leukemia ProteinLeukemia P388Leukemia, Biphenotypic, AcuteFriend murine leukemia virusHL-60 CellsLeukemia-Lymphoma, Adult T-CellCytarabineLeukemia, Megakaryoblastic, AcuteAKR murine leukemia virusFusion Proteins, bcr-ablLeukemia, Myeloid, Chronic-PhaseBone MarrowAcute DiseaseRemission InductionPrecursor B-Cell Lymphoblastic Leukemia-LymphomaAntineoplastic AgentsDaunorubicinTumor Cells, CulturedLeukemia, Plasma CellLeukemia, Myeloid, Accelerated PhaseKaryotypingK562 CellsLeukemia, Prolymphocytic, T-CellHuman T-lymphotropic virus 1Cell LineLeukemia, ProlymphocyticNeoplasm ProteinsCore Binding Factor Alpha 2 SubunitLeukemia, Myelomonocytic, JuvenilePrecursor T-Cell Lymphoblastic Leukemia-LymphomaLeukemia, Basophilic, AcuteBase SequenceLeukemic InfiltrationAsparaginasefms-Like Tyrosine Kinase 3Philadelphia ChromosomeLymphomaLeukemia, Myeloid, Chronic, Atypical, BCR-ABL NegativeMolecular Sequence DataApoptosisGraft vs Leukemia EffectAbelson murine leukemia virusChromosome AberrationsAntineoplastic Combined Chemotherapy ProtocolsLeukemia Inhibitory Factor Receptor alpha SubunitPreleukemiaPrognosisImmunophenotypingNeoplasm, ResidualBone Marrow TransplantationLeukemia, Large Granular LymphocyticCytogenetic AnalysisRetroviridaeCell DifferentiationDrug Resistance, NeoplasmRecurrenceFlow CytometryNeoplastic Stem CellsRetroviridae InfectionsHematopoietic Stem CellsCell Line, TumorOxidesGene Products, taxTreatment OutcomeMutationArsenicalsGene RearrangementIdarubicinVidarabineLeukemia Virus, Gibbon ApeDNA, NeoplasmChromosomes, Human, Pair 21Cell Transformation, NeoplasticTretinoinB-LymphocytesMyeloid Cell Leukemia Sequence 1 ProteinGenes, ablTranscription FactorsT-LymphocytesTransplantation, HomologousLeukemia, FelineCytogeneticsRNA, MessengerProto-Oncogene ProteinsCladribineChromosomes, Human, Pair 11Growth InhibitorsBurkitt LymphomaProto-OncogenesDisease-Free SurvivalCell DivisionPolymerase Chain ReactionDNA-Binding ProteinsHematopoietic Stem Cell TransplantationMice, Inbred AKRSurvival AnalysisEnzootic Bovine Leukosis6-MercaptopurineAntigens, NeoplasmAntibodies, MonoclonalRNA, NeoplasmMethotrexateTime FactorsAntigens, CDChromosomes, Human, 21-22 and YSurvival RateVincristineLeukemia, Mast-CellCell SurvivalClone CellsNuclear ProteinsNeoplasms, Second PrimaryReceptors, OSM-LIFReverse Transcriptase Polymerase Chain ReactionRadiation Leukemia VirusSialic Acid Binding Ig-like Lectin 3Leukemia, Neutrophilic, ChronicLymphocytesMice, SCIDThioguanineProtein Kinase InhibitorsProvirusesCells, CulturedAmino Acid SequenceGranulocytesSignal TransductionIn Situ Hybridization, FluorescenceAntimetabolites, AntineoplasticChromosomes, Human, Pair 8PentostatinDeltaretrovirusJurkat CellsDNA, ViralCell ProliferationTranscription, GeneticProto-Oncogene Proteins c-bcl-2Leukocyte CountDrug Screening Assays, AntitumorAntibiotics, AntineoplasticDose-Response Relationship, DrugGraft vs Host DiseaseTransfectionAntigens, CD34Myeloproliferative DisordersCyclophosphamideLeukemia, Prolymphocytic, B-CellEtoposideBlotting, SouthernOncogenesDeltaretrovirus InfectionsAntigens, SurfaceHematopoiesisChlorambucilGene Expression Regulation, NeoplasticChromosomes, Human, Pair 17Protein-Tyrosine KinasesDrug SynergismImmunoglobulin Heavy ChainsPhenotypeChromosomes, Human, Pair 12Neoplasm TransplantationChromosome DisordersArabinonucleosidesMitoxantroneGammaretrovirusHTLV-I InfectionsCombined Modality TherapyGenes, ViralMice, Inbred StrainsCell CycleProto-Oncogene Proteins c-bcrCell Transformation, ViralGene Expression ProfilingAntigens, CD38Tumor Suppressor ProteinsAntigens, CD19Gene ExpressionHarringtoninesRNA-Directed DNA PolymeraseRetrospective StudiesTumor Stem Cell AssayTumor Virus InfectionsAntibodies, Neoplasm
Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)Leukemia, Myeloid, Acute: Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.Leukemia, Lymphocytic, Chronic, B-Cell: A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.Leukemia, Lymphoid: Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.Leukemia, Experimental: Leukemia induced experimentally in animals by exposure to leukemogenic agents, such as VIRUSES; RADIATION; or by TRANSPLANTATION of leukemic tissues.Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.Leukemia Virus, Murine: Species of GAMMARETROVIRUS, containing many well-defined strains, producing leukemia in mice. Disease is commonly induced by injecting filtrates of propagable tumors into newborn mice.Precursor Cell Lymphoblastic Leukemia-Lymphoma: A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.Leukemia, T-Cell: A malignant disease of the T-LYMPHOCYTES in the bone marrow, thymus, and/or blood.Leukemia, Monocytic, Acute: An acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage including monoblasts, promonocytes, and MONOCYTES.Moloney murine leukemia virus: A strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) arising during the propagation of S37 mouse sarcoma, and causing lymphoid leukemia in mice. It also infects rats and newborn hamsters. It is apparently transmitted to embryos in utero and to newborns through mother's milk.Leukemia, Hairy Cell: A neoplastic disease of the lymphoreticular cells which is considered to be a rare type of chronic leukemia; it is characterized by an insidious onset, splenomegaly, anemia, granulocytopenia, thrombocytopenia, little or no lymphadenopathy, and the presence of "hairy" or "flagellated" cells in the blood and bone marrow.Leukemia L1210Leukemia, B-Cell: A malignant disease of the B-LYMPHOCYTES in the bone marrow and/or blood.Leukemia Virus, Bovine: The type species of DELTARETROVIRUS that causes a form of bovine lymphosarcoma (ENZOOTIC BOVINE LEUKOSIS) or persistent lymphocytosis.Leukemia Virus, Feline: A species of GAMMARETROVIRUS causing leukemia, lymphosarcoma, immune deficiency, or other degenerative diseases in cats. Several cellular oncogenes confer on FeLV the ability to induce sarcomas (see also SARCOMA VIRUSES, FELINE).Gene Expression Regulation, Leukemic: Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in leukemia.Leukemia, Radiation-Induced: Leukemia produced by exposure to IONIZING RADIATION or NON-IONIZING RADIATION.Myeloid-Lymphoid Leukemia Protein: Myeloid-lymphoid leukemia protein is a transcription factor that maintains high levels of HOMEOTIC GENE expression during development. The GENE for myeloid-lymphoid leukemia protein is commonly disrupted in LEUKEMIA and combines with over 40 partner genes to form FUSION ONCOGENE PROTEINS.Leukemia P388: An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.Leukemia, Biphenotypic, Acute: An acute leukemia exhibiting cell features characteristic of both the myeloid and lymphoid lineages and probably arising from MULTIPOTENT STEM CELLS.Friend murine leukemia virus: A strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) producing leukemia of the reticulum-cell type with massive infiltration of liver, spleen, and bone marrow. It infects DBA/2 and Swiss mice.HL-60 Cells: A promyelocytic cell line derived from a patient with ACUTE PROMYELOCYTIC LEUKEMIA. HL-60 cells lack specific markers for LYMPHOID CELLS but express surface receptors for FC FRAGMENTS and COMPLEMENT SYSTEM PROTEINS. They also exhibit phagocytic activity and responsiveness to chemotactic stimuli. (From Hay et al., American Type Culture Collection, 7th ed, pp127-8)Leukemia-Lymphoma, Adult T-Cell: Aggressive T-Cell malignancy with adult onset, caused by HUMAN T-LYMPHOTROPIC VIRUS 1. It is endemic in Japan, the Caribbean basin, Southeastern United States, Hawaii, and parts of Central and South America and sub-Saharan Africa.Cytarabine: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)Leukemia, Megakaryoblastic, Acute: An acute myeloid leukemia in which 20-30% of the bone marrow or peripheral blood cells are of megakaryocyte lineage. MYELOFIBROSIS or increased bone marrow RETICULIN is common.AKR murine leukemia virus: A strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) isolated from spontaneous leukemia in AKR strain mice.Fusion Proteins, bcr-abl: Translation products of a fusion gene derived from CHROMOSOMAL TRANSLOCATION of C-ABL GENES to the genetic locus of the breakpoint cluster region gene on chromosome 22. Several different variants of the bcr-abl fusion proteins occur depending upon the precise location of the chromosomal breakpoint. These variants can be associated with distinct subtypes of leukemias such as PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; and NEUTROPHILIC LEUKEMIA, CHRONIC.Leukemia, Myeloid, Chronic-Phase: The initial phase of chronic myeloid leukemia consisting of an relatively indolent period lasting from 4 to 7 years. Patients range from asymptomatic to those exhibiting ANEMIA; SPLENOMEGALY; and increased cell turnover. There are 5% or fewer blast cells in the blood and bone marrow in this phase.Bone Marrow: The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.Acute Disease: Disease having a short and relatively severe course.Remission Induction: Therapeutic act or process that initiates a response to a complete or partial remission level.Precursor B-Cell Lymphoblastic Leukemia-Lymphoma: A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.Tumor Cells, Cultured: Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.Leukemia, Plasma Cell: A rare, aggressive variant of MULTIPLE MYELOMA characterized by the circulation of excessive PLASMA CELLS in the peripheral blood. It can be a primary manifestation of multiple myeloma or develop as a terminal complication during the disease.Leukemia, Myeloid, Accelerated Phase: The phase of chronic myeloid leukemia following the chronic phase (LEUKEMIA, MYELOID, CHRONIC-PHASE), where there are increased systemic symptoms, worsening cytopenias, and refractory LEUKOCYTOSIS.Karyotyping: Mapping of the KARYOTYPE of a cell.K562 Cells: An ERYTHROLEUKEMIA cell line derived from a CHRONIC MYELOID LEUKEMIA patient in BLAST CRISIS.Leukemia, Prolymphocytic, T-Cell: A lymphoid leukemia characterized by a profound LYMPHOCYTOSIS with or without LYMPHADENOPATHY, hepatosplenomegaly, frequently rapid progression, and short survival. It was formerly called T-cell chronic lymphocytic leukemia.Human T-lymphotropic virus 1: A strain of PRIMATE T-LYMPHOTROPIC VIRUS 1 isolated from mature T4 cells in patients with T-lymphoproliferation malignancies. It causes adult T-cell leukemia (LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED), T-cell lymphoma (LYMPHOMA, T-CELL), and is involved in mycosis fungoides, SEZARY SYNDROME and tropical spastic paraparesis (PARAPARESIS, TROPICAL SPASTIC).Cell Line: Established cell cultures that have the potential to propagate indefinitely.Leukemia, Prolymphocytic: A chronic leukemia characterized by a large number of circulating prolymphocytes. It can arise spontaneously or as a consequence of transformation of CHRONIC LYMPHOCYTIC LEUKEMIA.Neoplasm Proteins: Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.Core Binding Factor Alpha 2 Subunit: A transcription factor that dimerizes with the cofactor CORE BINDING FACTOR BETA SUBUNIT to form core binding factor. It contains a highly conserved DNA-binding domain known as the runt domain. Runx1 is frequently mutated in human LEUKEMIAS.Leukemia, Myelomonocytic, Juvenile: A leukemia affecting young children characterized by SPLENOMEGALY, enlarged lymph nodes, rashes, and hemorrhages. Traditionally classed as a myeloproliferative disease, it is now considered a mixed myeloproliferative-mylelodysplastic disorder.Precursor T-Cell Lymphoblastic Leukemia-Lymphoma: A leukemia/lymphoma found predominately in children and young adults and characterized LYMPHADENOPATHY and THYMUS GLAND involvement. It most frequently presents as a lymphoma, but a leukemic progression in the bone marrow is common.Leukemia, Basophilic, Acute: A rare acute myeloid leukemia in which the primary differentiation is to BASOPHILS. It is characterized by an extreme increase of immature basophilic granulated cells in the bone marrow and blood. Mature basophils are usually sparse.Base Sequence: The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.Leukemic Infiltration: A pathologic change in leukemia in which leukemic cells permeate various organs at any stage of the disease. All types of leukemia show various degrees of infiltration, depending upon the type of leukemia. The degree of infiltration may vary from site to site. The liver and spleen are common sites of infiltration, the greatest appearing in myelocytic leukemia, but infiltration is seen also in the granulocytic and lymphocytic types. The kidney is also a common site and of the gastrointestinal system, the stomach and ileum are commonly involved. In lymphocytic leukemia the skin is often infiltrated. The central nervous system too is a common site.Asparaginase: A hydrolase enzyme that converts L-asparagine and water to L-aspartate and NH3. EC 3.5.1.1.fms-Like Tyrosine Kinase 3: A receptor tyrosine kinase that is involved in HEMATOPOIESIS. It is closely related to FMS PROTO-ONCOGENE PROTEIN and is commonly mutated in acute MYELOID LEUKEMIA.Philadelphia Chromosome: An aberrant form of human CHROMOSOME 22 characterized by translocation of the distal end of chromosome 9 from 9q34, to the long arm of chromosome 22 at 22q11. It is present in the bone marrow cells of 80 to 90 per cent of patients with chronic myelocytic leukemia (LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE).Lymphoma: A general term for various neoplastic diseases of the lymphoid tissue.Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative: A myelodysplastic/myeloproliferative disorder characterized by myelodysplasia associated with bone marrow and peripheral blood patterns similar to CHRONIC MYELOID LEUKEMIA, but cytogenetically lacking a PHILADELPHIA CHROMOSOME or bcr/abl fusion gene (GENES, ABL).Molecular Sequence Data: Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.Apoptosis: One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.Graft vs Leukemia Effect: Immunological rejection of leukemia cells following bone marrow transplantation.Abelson murine leukemia virus: A replication-defective strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) capable of transforming lymphoid cells and producing a rapidly progressing lymphoid leukemia after superinfection with FRIEND MURINE LEUKEMIA VIRUS; MOLONEY MURINE LEUKEMIA VIRUS; or RAUSCHER VIRUS.Chromosome Aberrations: Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS.Antineoplastic Combined Chemotherapy Protocols: The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.Leukemia Inhibitory Factor Receptor alpha Subunit: A receptor subunit that combines with CYTOKINE RECEPTOR GP130 to form the dual specificity receptor for LEUKEMIA INHIBITORY FACTOR and ONCOSTATIN M. The subunit is also a component of the CILIARY NEUROTROPHIC FACTOR RECEPTOR. Both membrane-bound and secreted isoforms of the receptor subunit exist due to ALTERNATIVE SPLICING of its mRNA. The secreted isoform is believed to act as an inhibitory receptor, while the membrane-bound form is a signaling receptor.Preleukemia: Conditions in which the abnormalities in the peripheral blood or bone marrow represent the early manifestations of acute leukemia, but in which the changes are not of sufficient magnitude or specificity to permit a diagnosis of acute leukemia by the usual clinical criteria.Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Immunophenotyping: Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry.Neoplasm, Residual: Remnant of a tumor or cancer after primary, potentially curative therapy. (Dr. Daniel Masys, written communication)Bone Marrow Transplantation: The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.Leukemia, Large Granular Lymphocytic: A spectrum of disorders characterized by clonal expansions of the peripheral blood LYMPHOCYTE populations known as large granular lymphocytes which contain abundant cytoplasm and azurophilic granules. Subtypes develop from either CD3-negative NATURAL KILLER CELLS or CD3-positive T-CELLS. The clinical course of both subtypes can vary from spontaneous regression to progressive, malignant disease.Cytogenetic Analysis: Examination of CHROMOSOMES to diagnose, classify, screen for, or manage genetic diseases and abnormalities. Following preparation of the sample, KARYOTYPING is performed and/or the specific chromosomes are analyzed.Retroviridae: Family of RNA viruses that infects birds and mammals and encodes the enzyme reverse transcriptase. The family contains seven genera: DELTARETROVIRUS; LENTIVIRUS; RETROVIRUSES TYPE B, MAMMALIAN; ALPHARETROVIRUS; GAMMARETROVIRUS; RETROVIRUSES TYPE D; and SPUMAVIRUS. A key feature of retrovirus biology is the synthesis of a DNA copy of the genome which is integrated into cellular DNA. After integration it is sometimes not expressed but maintained in a latent state (PROVIRUSES).Cell Differentiation: Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.Drug Resistance, Neoplasm: Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.Recurrence: The return of a sign, symptom, or disease after a remission.Flow Cytometry: Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.Neoplastic Stem Cells: Highly proliferative, self-renewing, and colony-forming stem cells which give rise to NEOPLASMS.Retroviridae Infections: Virus diseases caused by the RETROVIRIDAE.Hematopoietic Stem Cells: Progenitor cells from which all blood cells derive.Cell Line, Tumor: A cell line derived from cultured tumor cells.Oxides: Binary compounds of oxygen containing the anion O(2-). The anion combines with metals to form alkaline oxides and non-metals to form acidic oxides.Gene Products, tax: Transcriptional trans-acting proteins of the promoter elements found in the long terminal repeats (LTR) of HUMAN T-LYMPHOTROPIC VIRUS 1 and HUMAN T-LYMPHOTROPIC VIRUS 2. The tax (trans-activator x; x is undefined) proteins act by binding to enhancer elements in the LTR.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Mutation: Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.Arsenicals: Inorganic or organic compounds that contain arsenic.Gene Rearrangement: The ordered rearrangement of gene regions by DNA recombination such as that which occurs normally during development.Idarubicin: An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.Vidarabine: A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.Leukemia Virus, Gibbon Ape: A species of GAMMARETROVIRUS causing leukemia in the gibbon ape. Natural transmission is by contact.DNA, Neoplasm: DNA present in neoplastic tissue.Chromosomes, Human, Pair 21: A specific pair of GROUP G CHROMOSOMES of the human chromosome classification.Cell Transformation, Neoplastic: Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).B-Lymphocytes: Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.Myeloid Cell Leukemia Sequence 1 Protein: A member of the myeloid leukemia factor (MLF) protein family with multiple alternatively spliced transcript variants encoding different protein isoforms. In hematopoietic cells, it is located mainly in the nucleus, and in non-hematopoietic cells, primarily in the cytoplasm with a punctate nuclear localization. MLF1 plays a role in cell cycle differentiation.Genes, abl: Retrovirus-associated DNA sequences (abl) originally isolated from the Abelson murine leukemia virus (Ab-MuLV). The proto-oncogene abl (c-abl) codes for a protein that is a member of the tyrosine kinase family. The human c-abl gene is located at 9q34.1 on the long arm of chromosome 9. It is activated by translocation to bcr on chromosome 22 in chronic myelogenous leukemia.Transcription Factors: Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process.T-Lymphocytes: Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.Transplantation, Homologous: Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.Leukemia, Feline: A neoplastic disease of cats frequently associated with feline leukemia virus infection.Cytogenetics: A subdiscipline of genetics which deals with the cytological and molecular analysis of the CHROMOSOMES, and location of the GENES on chromosomes, and the movements of chromosomes during the CELL CYCLE.RNA, Messenger: RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.Proto-Oncogene Proteins: Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.Cladribine: An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.Chromosomes, Human, Pair 11: A specific pair of GROUP C CHROMOSOMES of the human chromosome classification.Growth Inhibitors: Endogenous or exogenous substances which inhibit the normal growth of human and animal cells or micro-organisms, as distinguished from those affecting plant growth (= PLANT GROWTH REGULATORS).Burkitt Lymphoma: A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.Proto-Oncogenes: Normal cellular genes homologous to viral oncogenes. The products of proto-oncogenes are important regulators of biological processes and appear to be involved in the events that serve to maintain the ordered procession through the cell cycle. Proto-oncogenes have names of the form c-onc.Disease-Free Survival: Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.Cell Division: The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.Polymerase Chain Reaction: In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.DNA-Binding Proteins: Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases.Hematopoietic Stem Cell Transplantation: Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.Mice, Inbred AKRSurvival Analysis: A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.Enzootic Bovine Leukosis: A lymphoid neoplastic disease in cattle caused by the bovine leukemia virus. Enzootic bovine leukosis may take the form of lymphosarcoma, malignant lymphoma, or leukemia but the presence of malignant cells in the blood is not a consistent finding.6-Mercaptopurine: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.Antigens, Neoplasm: Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.RNA, Neoplasm: RNA present in neoplastic tissue.Methotrexate: An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Antigens, CD: Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.Chromosomes, Human, 21-22 and Y: The short, acrocentric human chromosomes, called group G in the human chromosome classification. This group consists of chromosome pairs 21 and 22 and the Y chromosome.Survival Rate: The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.Vincristine: An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)Leukemia, Mast-Cell: A form of systemic mastocytosis (MASTOCYTOSIS, SYSTEMIC) characterized by the presence of large numbers of tissue MAST CELLS in the peripheral blood without skin lesions. It is a high-grade LEUKEMIA disease with bone marrow smear of >20% MAST CELLS, multi-organ failure and a short survival.Cell Survival: The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.Clone Cells: A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed)Nuclear Proteins: Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus.Neoplasms, Second Primary: Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.Receptors, OSM-LIF: Cell surface receptors formed from the dimerization of LIF RECEPTOR ALPHA SUBUNIT with CYTOKINE RECEPTOR GP130. Although originally described as receptors for LEUKEMIA INHIBITORY FACTOR these receptors also bind the closely-related protein ONCOSTATIN M and are referred to as both LIF receptors and type I oncostatin M receptors.Reverse Transcriptase Polymerase Chain Reaction: A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.Radiation Leukemia Virus: A strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) isolated from radiation-induced lymphomas in C57BL mice. It is leukemogenic, thymotrophic, can be transmitted vertically, and replicates only in vivo.Sialic Acid Binding Ig-like Lectin 3: A 67-kDa sialic acid binding lectin that is specific for MYELOID CELLS and MONOCYTE-MACROPHAGE PRECURSOR CELLS. This protein is the smallest siglec subtype and contains a single immunoglobulin C2-set domain. It may play a role in intracellular signaling via its interaction with SHP-1 PROTEIN-TYROSINE PHOSPHATASE and SHP-2 PROTEIN-TYROSINE PHOSPHATASE.Leukemia, Neutrophilic, Chronic: A rare myeloproliferative disorder that is characterized by a sustained, mature neutrophilic leukocytosis. No monocytosis, EOSINOPHILIA, or basophilia is present, nor is there a PHILADELPHIA CHROMOSOME or bcr-abl fusion gene (GENES, ABL).Lymphocytes: White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.Mice, SCID: Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.Thioguanine: An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.Protein Kinase Inhibitors: Agents that inhibit PROTEIN KINASES.Proviruses: Duplex DNA sequences in eukaryotic chromosomes, corresponding to the genome of a virus, that are transmitted from one cell generation to the next without causing lysis of the host. Proviruses are often associated with neoplastic cell transformation and are key features of retrovirus biology.Cells, Cultured: Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.Amino Acid Sequence: The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.Granulocytes: Leukocytes with abundant granules in the cytoplasm. They are divided into three groups according to the staining properties of the granules: neutrophilic, eosinophilic, and basophilic. Mature granulocytes are the NEUTROPHILS; EOSINOPHILS; and BASOPHILS.Signal Transduction: The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.In Situ Hybridization, Fluorescence: A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.Antimetabolites, Antineoplastic: Antimetabolites that are useful in cancer chemotherapy.Chromosomes, Human, Pair 8: A specific pair of GROUP C CHROMOSOMES of the human chromosome classification.Pentostatin: A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.Deltaretrovirus: A genus in the family RETROVIRIDAE consisting of exogenous horizontally-transmitted viruses found in a few groups of mammals. Infections caused by these viruses include human B- or adult T-cell leukemia/lymphoma (LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED), and bovine leukemia (ENZOOTIC BOVINE LEUKOSIS). The type species is LEUKEMIA VIRUS, BOVINE.Jurkat Cells: A CELL LINE derived from human T-CELL LEUKEMIA and used to determine the mechanism of differential susceptibility to anti-cancer drugs and radiation.DNA, Viral: Deoxyribonucleic acid that makes up the genetic material of viruses.Cell Proliferation: All of the processes involved in increasing CELL NUMBER including CELL DIVISION.Transcription, Genetic: The biosynthesis of RNA carried out on a template of DNA. The biosynthesis of DNA from an RNA template is called REVERSE TRANSCRIPTION.Proto-Oncogene Proteins c-bcl-2: Membrane proteins encoded by the BCL-2 GENES and serving as potent inhibitors of cell death by APOPTOSIS. The proteins are found on mitochondrial, microsomal, and NUCLEAR MEMBRANE sites within many cell types. Overexpression of bcl-2 proteins, due to a translocation of the gene, is associated with follicular lymphoma.Leukocyte Count: The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells.Drug Screening Assays, Antitumor: Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.Antibiotics, Antineoplastic: Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.Dose-Response Relationship, Drug: The relationship between the dose of an administered drug and the response of the organism to the drug.Graft vs Host Disease: The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.Transfection: The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.Antigens, CD34: Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.Myeloproliferative Disorders: Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.Cyclophosphamide: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.Leukemia, Prolymphocytic, B-Cell: A neoplasm of prolymphocytes affecting the blood, bone marrow, and spleen. It is characterized by prolymphocytes exceeding 55% of the lymphoid cells in the blood and profound splenomegaly.Etoposide: A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.Blotting, Southern: A method (first developed by E.M. Southern) for detection of DNA that has been electrophoretically separated and immobilized by blotting on nitrocellulose or other type of paper or nylon membrane followed by hybridization with labeled NUCLEIC ACID PROBES.Oncogenes: Genes whose gain-of-function alterations lead to NEOPLASTIC CELL TRANSFORMATION. They include, for example, genes for activators or stimulators of CELL PROLIFERATION such as growth factors, growth factor receptors, protein kinases, signal transducers, nuclear phosphoproteins, and transcription factors. A prefix of "v-" before oncogene symbols indicates oncogenes captured and transmitted by RETROVIRUSES; the prefix "c-" before the gene symbol of an oncogene indicates it is the cellular homolog (PROTO-ONCOGENES) of a v-oncogene.Deltaretrovirus Infections: Infections caused by the HTLV or BLV deltaretroviruses. They include human T-cell leukemia-lymphoma (LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED).Antigens, Surface: Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated.Hematopoiesis: The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY).Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)Gene Expression Regulation, Neoplastic: Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.Chromosomes, Human, Pair 17: A specific pair of GROUP E CHROMOSOMES of the human chromosome classification.Protein-Tyrosine Kinases: Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors.Drug Synergism: The action of a drug in promoting or enhancing the effectiveness of another drug.Immunoglobulin Heavy Chains: The largest of polypeptide chains comprising immunoglobulins. They contain 450 to 600 amino acid residues per chain, and have molecular weights of 51-72 kDa.Phenotype: The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.Chromosomes, Human, Pair 12: A specific pair of GROUP C CHROMOSOMES of the human chromosome classification.Neoplasm Transplantation: Experimental transplantation of neoplasms in laboratory animals for research purposes.Chromosome Disorders: Clinical conditions caused by an abnormal chromosome constitution in which there is extra or missing chromosome material (either a whole chromosome or a chromosome segment). (from Thompson et al., Genetics in Medicine, 5th ed, p429)Arabinonucleosides: Nucleosides containing arabinose as their sugar moiety.Mitoxantrone: An anthracenedione-derived antineoplastic agent.Gammaretrovirus: A genus of RETROVIRIDAE comprising endogenous sequences in mammals, related RETICULOENDOTHELIOSIS VIRUSES, AVIAN, and a reptilian virus. Many species contain oncogenes and cause leukemias and sarcomas.HTLV-I InfectionsCombined Modality Therapy: The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.Genes, Viral: The functional hereditary units of VIRUSES.Mice, Inbred Strains: Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.Cell Cycle: The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE.Proto-Oncogene Proteins c-bcr: Proto-oncogene protein bcr is a serine-threonine kinase that functions as a negative regulator of CELL PROLIFERATION and NEOPLASTIC CELL TRANSFORMATION. It is commonly fused with cellular abl protein to form BCR-ABL FUSION PROTEINS in PHILADELPHIA CHROMOSOME positive LEUKEMIA patients.Cell Transformation, Viral: An inheritable change in cells manifested by changes in cell division and growth and alterations in cell surface properties. It is induced by infection with a transforming virus.Gene Expression Profiling: The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.Antigens, CD38: A bifunctional enzyme that catalyzes the synthesis and HYDROLYSIS of CYCLIC ADP-RIBOSE (cADPR) from NAD+ to ADP-RIBOSE. It is a cell surface molecule which is predominantly expressed on LYMPHOID CELLS and MYELOID CELLS.Tumor Suppressor Proteins: Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.Antigens, CD19: Differentiation antigens expressed on B-lymphocytes and B-cell precursors. They are involved in regulation of B-cell proliferation.Gene Expression: The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.Harringtonines: Tetracyclic spiro-BENZAZEPINES isolated from the seeds of CEPHALOTAXUS. They are esters of the alkaloid cephalotaxine and may be effective as antineoplastic agents.RNA-Directed DNA Polymerase: An enzyme that synthesizes DNA on an RNA template. It is encoded by the pol gene of retroviruses and by certain retrovirus-like elements. EC 2.7.7.49.Retrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.Tumor Stem Cell Assay: A cytologic technique for measuring the functional capacity of tumor stem cells by assaying their activity. It is used primarily for the in vitro testing of antineoplastic agents.Tumor Virus Infections: Infections produced by oncogenic viruses. The infections caused by DNA viruses are less numerous but more diverse than those caused by the RNA oncogenic viruses.Antibodies, Neoplasm: Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.

Incidence and occupational pattern of leukaemias, lymphomas, and testicular tumours in western Ireland over an 11 year period. (1/5761)

STUDY OBJECTIVE: To determine incidence of the following malignancies, testicular tumours, all leukaemias and all lymphomas in the West of Ireland in an 11 year period. Secondly, to examine the relation between disease patterns and available occupational data in male subjects of working age. DESIGN: A census survey of all cases occurring in the three counties in the Western Health Board (WHB) area, Galway, Mayo and Roscommon, for the 11 year period 1980 to 1990 inclusive. Average annual age standardised incidence rates for the period were calculated using the 1986 census data. Rates for the area are compared with rates from the southern region of Ireland, which had a tumour registry. Trends over the time period are evaluated. All male subjects for whom occupational data were available were categorised using the Irish socioeconomic group classification and incidence rates by occupation were compared using the standardised incidence ratio method. In one of the counties, Galway, a detailed occupational history of selected cases and an age matched control group was also elicited through patients' general practitioners. SETTING: All available case records in the West of Ireland. RESULTS: There are no national incidence records for the period. Compared with data from the Southern Tumour Registry, the number of cases of women with myeloid leukaemias was significantly lower. Male leukaemia rates were significantly lower as a group (SIR 84 (95% CI 74, 95) but not when considered as individual categories. Regression analysis revealed an increasing trend in the number of new cases of non-Hodgkin's lymphoma among both men (r = 0.47, p = 0.02) and women (r = 0.90, p = 0.0001) and of chronic lymphocytic leukaemia in men (r = 0.77, p = 0.005) and women (r = 0.68 p = 0.02) in the WHB region over the last decade. Four hundred and fifty six male cases over the age of 15 years were identified and adequate occupational information was available for 74% of these. Standardised incidence ratios of testicular tumours 100, 938) and agriworkers other than farmers (SIR 377, 95% CI 103, 967). There were also significantly increased incidence ratios for both non-Hodgkin's lymphoma (SIR 169, 95% CI 124, 266) and three categories of leukaemias among farmers. Hodgkin's disease and acute myeloid leukaemias were significantly increased among semi-skilled people. Interview data with 90 cases and 54 controls of both sexes revealed that among farmers, cases (n = 31) were significantly less likely than controls (n = 20) to use tractor mounted spraying techniques (OR = 0.19 (95% CI 0.04, 0.80)) and less likely to wear protective masks (OR 0.22 (95% CI 0.05, 0.84)). CONCLUSIONS: Trends of increase in non-Hodgkin's lymphoma and some leukaemias are consistent with studies elsewhere. The study provides further evidence of the relation between agricultural work and certain lymphoproliferative cancers. The possible carcinogenic role of chemicals used in agricultural industries must be considered as an explanation.  (+info)

Tissue specific expression and chromosomal mapping of a human UDP-N-acetylglucosamine: alpha1,3-d-mannoside beta1, 4-N-acetylglucosaminyltransferase. (2/5761)

A human cDNA for UDP- N -acetylglucosamine:alpha1,3-d-mannoside beta1,4- N- acetylglucosaminyltransferase (GnT-IV) was isolated from a liver cDNA library using a probe based on a partial cDNA sequence of the bovine GnT-IV. The cDNA encoded a complete sequence of a type II membrane protein of 535 amino acids which is 96% identical to the bovine GnT-IV. Transient expression of the human cDNA in COS7 cells increased total cellular GnT-IV activity 25-fold, demonstrating that this cDNA encodes a functional human GnT-IV. Northern blot analysis of normal tissues indicated that at least five different sizes of mRNA (9.7, 7.6, 5.1, 3.8, and 2.4 kb) forGnT-IV are expressed in vivo. Furthermore, these mRNAs are expressed at different levels between tissues. Large amounts of mRNA were detected in tissues harboring T lineage cells. Also, the promyelocytic leukemia cell line HL-60 and the lymphoblastic leukemia cell line MOLT-4 revealed abundant mRNA. Lastly, the gene was mapped at the locus on human chromosome 2, band q12 by fluorescent in situ hybridization.  (+info)

Bone marrow transplantation in pediatric patients with therapy-related myelodysplasia and leukemia. (3/5761)

Eleven children underwent BMT for therapy-related MDS or leukemia, four from HLA-identical siblings and seven from unrelated donors. Ten of the 11 were conditioned with busulfan and cyclophosphamide as the majority had received prior irradiation to the chest and/or abdomen. All patients engrafted. Regimen-related toxicity was more common when compared to historical controls. Eight patients developed acute GVHD and four of eight who survived 100 days post transplant developed extensive chronic GVHD. Non-relapse related mortality occurred in three patients. Five patients developed recurrent malignancy: one died from recurrence of osteosarcoma, three died of recurrent leukemia or MDS and another developed two subsequent malignancies (duodenal carcinoma and anaplastic astrocytoma). Three survive disease-free at 14+, 22+ and 43+ months for a 2 year actuarial cancer-free survival of 24% (95% confidence interval = 5-53%). Although allogeneic BMT can be curative, regimen-related toxicity is frequent and recurrent malignancy remains the major obstacle.  (+info)

Advances in therapy of multiple myeloma: lessons from acute leukemia. (4/5761)

This paper traces the lack of progress, until recently, in the treatment of multiple myeloma (MM) to having ignored the principles that led to cure in acute leukemia more than 2 decades ago. Only in the mid-1980s did investigation begin to consider complete remission (CR) a research objective, representing a necessary first step toward cure. The experience with autologous and allogeneic stem cell-supported high-dose therapy is reviewed, demonstrating, in both historically controlled and randomized studies, the validity of the dose-response concept in MM in terms of increased CR rates as well as extended event-free (EFS) and overall survival (OS). Avoidance of hematopoietic stem cell-damaging agents, especially melphalan, nitrosoureas, and ionizing radiation to marrow-containing sites, assures the ability of peripheral stem cell collection of high quality and quantity, providing rapid engraftment so that mortality is well under 5% following high-dose melphalan (200 mg/m2). This treatment can be applied safely to patients even >70 years of age and in the presence of renal failure. Tandem autotransplants after multiregimen induction have yielded CR rates in the 40% range with median durations of EFS and OS of 43 and 62 months, respectively. Certain chromosomal abnormalities (11 and 13; and translocations) represent the dominant adverse prognosticator for EFS and OS, confirmed in over 500 patients including those with prior therapy. Allogeneic transplants, possible in less than 10% of MM patients, are associated with a 50% mortality during the first year and, unfortunately, late relapses; thus, this approach should be reserved for patients with high-risk disease early in their management. A risk-based treatment algorithm that matches a patient's disease risk with the risk of intervention is presently used, followed by bisphosphonate therapy, not only to delay the onset of MM-related bone disease but also to induce tumor cell apoptosis, indirectly or directly, by down-regulation of cytokines with antiapoptotic activities. Although many patients relapse, this author subscribes to his mentor's motto: "Be Prepared for Success!".  (+info)

The evolution of antibiotic therapy for neutropenic patients. (5/5761)

Considerable progress has been made in the treatment of infections in neutropenic patients during the past three decades. A major contribution to this progress has been the discovery of effective new therapies and their prompt administration. Unfortunately, successful therapy of each important pathogen has resulted in the emergence of new pathogens, usually with unique patterns of antibiotic susceptibility. Unfortunately, antibiotic resistance has become an increasing threat in recent years, raising the possibility of infections that will be difficult to eradicate. Fortunately, there are new classes of antimicrobials that hold promise for therapeutic success in the future.  (+info)

Toward a leukemia treatment strategy based on the probability of stem cell death: an essay in honor of Dr. Emil J Freireich. (6/5761)

Dr. Emil J Freireich is a pioneer in the rational treatment of cancer in general and leukemia in particular. This essay in his honor suggests that the cell kill concept of chemotherapy of acute myeloblastic leukemia be extended to include two additional ideas. The first concept is that leukemic blasts, like normal hemopoietic cells, are organized in hierarchies, headed by stem cells. In both normal and leukemic hemopoiesis, killing stem cells will destroy the system; furthermore, both normal and leukemic cells respond to regulators. It follows that acute myelogenous leukemia should be considered as a dependent neoplasm. The second concept is that cell/drug interaction should be considered as two phases. The first, or proximal phase, consists of the events that lead up to injury; the second, or distal phase, comprises the responses of the cell that contribute to either progression to apoptosis or recovery. Distal responses are described briefly. Regulated drug sensitivity is presented as an example of how distal responses might be used to improve treatment.  (+info)

Oncogenes and tumor suppressor genes: therapeutic implications. (7/5761)

Genetic instability is a hallmark of cancer. Alterations in DNA through mutations, deletions, and translocations affect genes that are fundamental to normal cell growth differentiation and programmed cell death. Here, we discuss these alterations as they relate to oncogenes and tumor suppressor genes. In addition, we describe the implications the changes in oncogenes and tumor suppressor genes have on designing new therapeutic strategies for the treatment of cancer.  (+info)

Cyclin A1 expression in leukemia and normal hematopoietic cells. (8/5761)

Human cyclin A1 is a newly cloned, tissue-specific cyclin that is prominently expressed in normal testis. In this study, we showed that cyclin A1 was highly expressed in a subset of leukemia samples from patients. The highest frequency of cyclin A1 overexpression was observed in acute myelocytic leukemias, especially those that were at the promyelocyte (M3) and myeloblast (M2) stages of development. Cyclin A1 expression was also detected in normal CD34(+) progenitor cells. The expression of cyclin A1 increased when these cells were stimulated to undergo myeloid differentiation in vitro. Taken together, our observations suggest that cyclin A1 may have a role in hematopoiesis. High levels of cyclin A1 expression are especially associated with certain leukemias blocked at the myeloblast and promyelocyte stages of differentiation.  (+info)

Acute nonlymphocytic leukemia. Causes, symptoms, treatment Acute nonlymphocytic leukemiaAcute nonlymphocytic leukemia. Causes, symptoms, treatment Acute nonlymphocytic leukemia
Description of disease Acute nonlymphocytic leukemia. Treatment Acute nonlymphocytic leukemia. Symptoms and causes Acute nonlymphocytic leukemia Prophylaxis Acute nonlymphocytic leukemia
Translocation t(12;19)(q13;q13.3). A new recurrent abnormality in acute nonlymphocytic leukemia with atypical erythropoiesis<...Translocation t(12;19)(q13;q13.3). A new recurrent abnormality in acute nonlymphocytic leukemia with atypical erythropoiesis<...
TY - JOUR. T1 - Translocation t(12;19)(q13;q13.3). A new recurrent abnormality in acute nonlymphocytic leukemia with atypical erythropoiesis. AU - Paietta, Elisabeth M.. AU - Papenhausen, Peter. AU - Gucalp, Rasim A.. AU - Wiernik, Peter H.. PY - 1988. Y1 - 1988. N2 - A new reciprocal, apparently balanced translocation between chromosomes 12 and 19, t(12;19)(q13;q13.3), was detected in 5% ( 3 59) of patients with FAB M1 or M2 acute nonlymphocytic leukemia. In either case, this translocation was part of complex but different cytogenetic abnormalities. None of the patients had a significant response to therapy. In one instance, however, the translocation was found at first relapse after 2 years of complete remission, and no information regarding the karyotype at disease onset was available. Hematologically common to these patients were marked marrow erythroid hyperplasia and severely abnormal erythropoiesis despite normal serum B12 and folate levels. A direct association between t(12;19) and these ...
Antiemetic Efficacy of High-Dose Dexamethasone in Induction Therapy in Acute Nonlymphocytic Leukemia | Annals of Internal...Antiemetic Efficacy of High-Dose Dexamethasone in Induction Therapy in Acute Nonlymphocytic Leukemia | Annals of Internal...
Nausea and vomiting continue to be distressing side effects of cancer chemotherapy. We recently reported (1) a randomized, double-blind study in which a single 10-mg dose of intravenous dexamethasone markedly reduced the gastrointestinal side effects of mildly emetogenic chemotherapy for outpatients with breast cancer. We now report the safety and efficacy of repeated doses of dexamethasone in eliminating the nausea and vomiting of induction chemotherapy for patients with acute nonlymphocytic leukemia.. All patients included in the study were adults with acute nonlymphocytic leukemia (at diagnosis or on relapse) at the Hospital of the University of Pennsylvania and were treated with ...
Adult Acute Leukemia synonyms, Adult Acute Leukemia antonyms - FreeThesaurus.comAdult Acute Leukemia synonyms, Adult Acute Leukemia antonyms - FreeThesaurus.com
Synonyms for Adult Acute Leukemia in Free Thesaurus. Antonyms for Adult Acute Leukemia. 1 synonym for acute myeloid leukemia: acute myelocytic leukemia. What are synonyms for Adult Acute Leukemia?
A Pilot Study of Recombinant Human Arginase 1 (rhArg1) in Patients With Relapsed or Refractory Leukemia or Lymphoma - Full Text...A Pilot Study of Recombinant Human Arginase 1 (rhArg1) in Patients With Relapsed or Refractory Leukemia or Lymphoma - Full Text...
This is a pilot, open-label study of PEG-BCT-100 in patients with relapsed/refractory leukemia or lymphoma who have satisfied all inclusion/exclusion criteria.. Approximately 15 subjects will be enrolled or when 10 evaluable subjects are included in the study. Evaluable subjects are defined as subjects who have received 4 consecutive doses of PEG-BCT-100 1600U/kg within 6 weeks from the first 1600U/kg dose and completed the first disease response assessment.. After the initiation of trial treatment, safety parameters will be evaluated throughout the study. Adverse event (AE) will be graded according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 4.0 (NCI CTC AE v4). AE and serious AE (SAE) will be detected and recorded on the Case Report Forms (CRFs) until 15-28 days after the last dose of PEG-BCT-100.. Patients who achieve complete remission (CR)/complete remission with incomplete blood count recovery (CRi) following the 4 consecutive 1600U/kg doses may ...
Leicester Research Archive: Biochemical characteristics of apoptosis in two human leukaemic cell lines.Leicester Research Archive: Biochemical characteristics of apoptosis in two human leukaemic cell lines.
Apoptosis is a form of cell death in which the cell actively participates. Apoptosis was induced in two human leukaemic cell lines, U937 and HL-60, by incubation with a diverse array of chemical agents. Cell death was assessed by gel electrophoresis, light microscopy and flow cytometry. It was demonstrated that apoptosis involved the formation of large kilobase pair DNA fragments (20-50, 145-245 and 580 kilobase pairs) prior to, or accompanying, internucleosomal cleavage. Degradation of DNA to large kilobase pair sizes also occurred in some forms of necrosis. These fragments were similar, but not identical, to those generated during apoptosis. The identity of the endonuclease(s) responsible for DNA cleavage to large kilobase pair fragments is as yet unknown. One suggestion is that topoisomerase II might be involved. Using an HL-60 subclone with reduced topoisomerase II expression, it was shown that topoisomerase II was not necessary for the formation of large kilobase pair DNA fragments and ...
Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic...Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic...
For patients with advanced leukemia undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), a major obstacle to success, especially in those with a high leukemia cell burden, is relapse of the underlying disease. To improve the outcome of allo-HSCT for refractory leukemia, we investigated the strategy of sequential intensified conditioning and early rapid tapering of prophylactic immunosuppressants therapy for graft-versus-host disease (GVHD) during the early stage after transplantation. A total of 51 patients with refractory leukemia (median age, 30.0 years; unfavorable karyotypes, 49%) received fludarabine (Flu) 30 mg/m(2)/day and cytarabine 2 g/m(2)/day (on days -10 to -6), 4.5 Gy total body irradiation (TBI)/day (on days -5 and -4), and cyclophosphamide (Cy) 60 mg/kg/day and etoposide 600 mg/day (on days -3 and -2) for conditioning. Cyclosporine A (CsA) was withdrawn rapidly in a stepwise fashion to avoid overwhelming GVHD reactions if acute GVHD (aGVHD) did not develop at ...
Symptoms Of Leukemia In Adults | Made ManSymptoms Of Leukemia In Adults | Made Man
Some of the symptoms of leukemia in adults will look like other diseases. Symptoms like fever, chills, weakness, bleeding, abdominal pain and more could also be symptoms for other cancers. Learn more about adult leukemia and how to know the exact symptoms to be careful of. Leukemia is cancer of the blood cells. Leukemia occurs when the white cells in the bone marrow start producing at an abnormal rate. Adult leukemia occurs mainly after the age of 55 and equals 90% of the total leukemia cases reported. Adult leukemia can be seen mainly in four different types: acute and chronic lymphocytic leukemia and acute and chronic myeloid leukemia. Adult leukemia brings on many symptoms, such as fever, night sweats, weight loss and tiny red spots under the skin. ...
Erythrocyte characteristics in childhood acute leukemia<...Erythrocyte characteristics in childhood acute leukemia<...
TY - JOUR. T1 - Erythrocyte characteristics in childhood acute leukemia. AU - Alter, Blanche P.. AU - Weiner, Michael A.. AU - Harris, Michael B.. PY - 1989. Y1 - 1989. N2 - Children with acute leukemia often have erythrocytes with "fetal-like" features. To examine the relationship of the type and phase of the leukemia to this observation, we studied 39 children with newly diagnosed acute lymphocytic leukemia (ALL) and 5 with acute nonlympho- cytic leukemia (ANLL). In addition, 22 patients were evaluated during chemotherapy, 3 off therapy, and 12 at the time of relapse. Macrocytosis and/or anisocytosis was noted in 70% of patients with ALL at the time of first diagnosis, 80% of patients with new ANLL, and ,90% of patients with ALL while on treatment. F cells were increased in 25% of ALL and 80% of ANLL at diagnosis and in 60% of ALL during chemotherapy. Hb F levels were elevated in 8, 40, and 30% of these groups, respectively. Nonleukemic controls for chemotherapy (six patients with osteogenic ...
Childhood Leukemia International ConsortiumChildhood Leukemia International Consortium
Relative to the chronic health problems that plague adults, such as cardiovascular disease and diabetes, childhood leukemia is a relatively rare disease. From an epidemiological perspective, this makes childhood leukemia more challenging to study, because the incidence rate limits the scope of the investigation. Moreover, childhood leukemia is actually a catch-all term for an amalgam of disease subtypes, which are etiologically and clinically distinct; each one having its own set of causes and range of outcomes. In addition, each of the childhood leukemia subtypes is potentially multifactorial, with several circumstances contributing to the initiation of each leukemia case. To account for the complexity of the disease, researchers must consider the cumulative impact of joint exposure to an overwhelming mixture of chemicals as well as the unique genetic susceptibility inherent in each child. Together, these two factors - exposure and genetics - must be considered in the context of the childs ...
Childhood leukemia - WikipediaChildhood leukemia - Wikipedia
Childhood leukemia is a type of leukemia, usually acute lymphocytic leukemia (ALL), and a type of childhood cancer. The cure rate of childhood leukemia is generally higher than adult leukemia, approaching 90%, although side effects of treatment last into adulthood. The older aggressive treatments of cranial irradiation and anthracyclines (such as doxorubicin) caused increased risk of solid tumors, heart failure, growth retardation, and cognitive defects. Leukemia is a hematological malignancy or a cancer of the blood. It develops in the bone marrow, the soft inner part of bones where new blood cells are made. When a child has leukemia, the bone marrow produces white blood cells that do not mature correctly. Normal healthy cells only reproduce when there is enough space for them. The body will regulate the production of cells by sending signals of when to stop production. When a child has leukemia, the cells do not respond to the signals telling them when to stop and when to produce cells, ...
Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome - Tabular...Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome - Tabular...
PRIMARY OBJECTIVES: I. To determine the recommended phase II doses for the combination of bortezomib and belinostat in patients with relapsed or refractory acute leukemia (AL), myelodysplasia (MDS), and chronic myelogenous leukemia in blast crisis. SECONDARY OBJECTIVES: I. Determine safety and tolerance and describe the toxicities of the combination. II. To demonstrate adequate methods for the assessment of pharmacodynamic response of leukemia cells from the bone marrow and/or peripheral blood in terms of effects on NF-kB (nuclear RelA by immunofluorescence microscopy), NF-kB dependent proteins XIAP and Bcl-xL, and BIM, and document pharmacodynamic responses observed in the course of this study. III. To document activity of the combination observed in the course of this study. OUTLINE: Patients receive belinostat IV over 30 minutes on days 1-5 and 8-12 and bortezomib IV on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or ...
CAR-T Cell Therapy Combination Shows Promise in Relapsed/Refractory LeukemiaCAR-T Cell Therapy Combination Shows Promise in Relapsed/Refractory Leukemia
Administering Imbruvica with CAR-T cell therapy improved outcomes in patients with chronic lymphocytic leukemia, according to recent research.
Socioeconomic disparities in survival from childhood leukemia in the United States and globally : a meta-analysisSocioeconomic disparities in survival from childhood leukemia in the United States and globally : a meta-analysis
BACKGROUND: Despite advancements in the treatment of childhood leukemia, socioeconomic status (SES) may potentially affect disease prognosis. This study aims to evaluate whether SES is associated with survival from childhood leukemia.. METHODS: The US National Cancer Institute Surveillance, Epidemiology and End Results Program (SEER) 1973-2010 data were analyzed; thereafter, results were meta-analyzed along with those from survival (cohort) studies examining the association between SES indices and survival from childhood leukemia (end-of-search date: 31 March 2014). Random-effects models were used to calculate pooled effect estimates (relative risks, RRs); meta-regression was also used.. RESULTS: We included 29 studies yielding 28 804 acute lymphoblastic leukemia (ALL), 3208 acute myeloblastic leukemia (AML) and 27 650 any leukemia (denoting joint reporting of all subtypes) cases. According to individual-level composite SES indices, children from low SES suffered from nearly twofold higher ...
Plus itPlus it
Background: Acute leukemia (AL) is a hematologic malignancy which posts a serious hazard to peoples health, especially that of childrens. At present, chemotherapy remains the most important therapeutic measure for AL. But there are 30% of patients who do not response to chemotherapy and 40%-60% of patients who become irresponsive eventually after relapse, which belong to refractory acute leukemia. Refractory acute leukemia (RAL), characterized by poor response to chemotherapy, low remission rate of induction chemotherapy and short-term survival, is a challenge for the treatment of AL. How to improve chemotherapy remission rate has always been essential to the treatment of refractory acute leukemia. To observe the effect of Compound Zhe Bei Granules (CZBG) combined with chemotherapy to improve clinical remission rate of patients with refractory acute leukemia, we designed this randomized multicenter, double-blind, placebo-controlled clinical trial under the guideline of Good Clinical Practice ...
Acute leukemia synonyms, acute leukemia antonyms - FreeThesaurus.comAcute leukemia synonyms, acute leukemia antonyms - FreeThesaurus.com
Synonyms for acute leukemia in Free Thesaurus. Antonyms for acute leukemia. 8 words related to acute leukemia: cancer of the blood, leucaemia, leukaemia, leukemia, acute lymphoblastic leukemia, acute lymphocytic leukemia.... What are synonyms for acute leukemia?
Acute Leukemia | Principles of Critical Care, 4e | AccessAnesthesiology | McGraw-Hill MedicalAcute Leukemia | Principles of Critical Care, 4e | AccessAnesthesiology | McGraw-Hill Medical
Acute leukemias are a collection of bone marrow and lymphoid disorders that result from establishment of a malignant stem cell population. Presentation of a patient to medical care with a suspected acute leukemia should be considered a medical emergency, and rapidly involve a specialist in hematologic malignancies and referral to a tertiary care facility with expertise in treatment of patients with acute leukemia. Left untreated, acute leukemias are rapidly fatal within days to weeks of presentation, but with appropriate supportive measures and therapeutic interventions a significant number of patients are cured. For those in whom a cure cannot be achieved, there is still the potential for a substantial period of good quality life. Because of the acuity of these diseases and consequences of their treatment, it is not infrequent that patients with acute leukemias are seen in the setting of a medical ICU.45 It is especially important to understand that acute leukemias develop rapidly and the ...
First clinical experiences with Gemtuzumab ozogamicin (GO, Mylotarg (c)) in CD33 positive relapsed/refractory leukemia in...First clinical experiences with Gemtuzumab ozogamicin (GO, Mylotarg (c)) in CD33 positive relapsed/refractory leukemia in...
Linköping University, Faculty of Health Sciences. Linköping University, Department of Clinical and Experimental Medicine, Pediatrics . Östergötlands Läns Landsting, Centre of Paediatrics and Gynecology and Obstetrics, Department of Paediatrics in Linköping. ...
Pro-apoptotic activity of α-bisabolol in preclinical models of primary human acute leukemia cells. | Sigma-AldrichPro-apoptotic activity of α-bisabolol in preclinical models of primary human acute leukemia cells. | Sigma-Aldrich
Sigma-Aldrich offers abstracts and full-text articles by [Elisabetta Cavalieri, Antonella Rigo, Massimiliano Bonifacio, Alessandra Carcereri de Prati, Emanuele Guardalben, Christian Bergamini, Romana Fato, Giovanni Pizzolo, Hisanori Suzuki, Fabrizio Vinante].
Preventing Childhood Leukemia May Eventually Be Possible. As A Survivor Myself, Im HopefulPreventing Childhood Leukemia May Eventually Be Possible. As A Survivor Myself, I'm Hopeful
A prominent UK scientist has suggested that childhood leukemia may one day be preventable by priming the immune systems of babies with harmless bacteria.
Cytotoxic effects of membrane-active agents in human leukaemia cell lines | Biochemical Society TransactionsCytotoxic effects of membrane-active agents in human leukaemia cell lines | Biochemical Society Transactions
Thank you for your interest in spreading the word about Biochemical Society Transactions.. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.. ...
Scientists modify CAR-T cells to target multiple sites on leukemia cellsScientists modify CAR-T cells to target multiple sites on leukemia cells
In a new pre-clinical study published this week in the journal Leukemia, the research team of Childrens Hospital Los Angeles investigator Hisham Abdel-Azim, MD, MS, worked with colleagues to engineer T-cells to identify and target multiple sites on acute lymphoblastic leukemia cells instead of just one. The early collaboration points the way to future clinical trials to test the therapy.
Determination of the Effects of Camptothecin on Cell Cycling and Apoptosis in Human Leukaemic Cell LinesDetermination of the Effects of Camptothecin on Cell Cycling and Apoptosis in Human Leukaemic Cell Lines
The Scientific World Journal is a peer-reviewed, Open Access journal covering a wide range of subjects in science, technology, and medicine. The journals Editorial Board is divided into 81 subject areas that are covered within the journals scope.
Inhibition of PI3-kinase sensitises HL60 human leukaemia cells to both chemotherapeutic drug- and Fas-induced apoptosis by a...Inhibition of PI3-kinase sensitises HL60 human leukaemia cells to both chemotherapeutic drug- and Fas-induced apoptosis by a...
Increasing resistance to chemotherapeutic regimes remains a serious problem in the treatment of acute myeloid leukaemia. We have shown that phosphatidylinositol (PI) 3-kinase inhibition significantly sensitises the AML derived cell line, HL60 to chemotherapeutic drug- and Fas-induced apoptosis. PI3-kinase inhibition significantly potentiates cytotoxic drug-induced c-jun N-terminal kinase (JNK) activation, reported to be a requirement for apoptosis. However, JNK inhibition does not enhance cell viability following treatment with drug and inhibitor. Furthermore, PI3-kinase inhibition significantly increases sensitivity to apoptosis mediated by an exogenous receptor agonist, again by a JNK independent mechanism. These results suggest that PI3-kinase inhibitors could be of significant therapeutic importance, lowering the threshold for apoptosis induced by both chemotherapy and cell-mediated immune response.
Anti-leukemic activity of phosphoproteins from Sesamin via induction of nuclear antigen H731and CLIP-associating protein 2...Anti-leukemic activity of phosphoproteins from Sesamin via induction of nuclear antigen H731and CLIP-associating protein 2...
Anti-leukemic activity of phosphoproteins from Sesamin via induction of nuclear antigen H731and CLIP-associating protein 2 isoform X25 mediated apoptosis
reagents-molecular-assay-chromosome-anomaly-translocation-t11;19q23p13.3reagents-molecular-assay-chromosome-anomaly-translocation-t11;19q23p13.3
Definition : Molecular assay reagents intended for use in identifying exchanges (i.e., translocations) between chromosome 11 band q23 and chromosome 19 band p13.3, usually involving genes MLL and ENL, respectively. This translocation is present in patients with both acute lymphoblastic leukemia and acute nonlymphocytic leukemia (ALL and ANLL, respectively); most cases are found in infants (congenital leukemia). Its detection may be used as a tumor marker.. Entry Terms : "Congenital Leukemia Diagnostic Reagents" , "Acute Non-Lymphocytic Leukemia Diagnostic Reagents" , "Acute Lymphoblastic Leukemia Diagnostic Reagents" , "Leukemia Diagnostic Reagents" , "Chromosome Translocation t(11;19)(q23p13.3) Detection Reagents" , "Reagents, Molecular Assay, Chromosome Anomaly, Translocation, t(11;19)(q23p13.3)". UMDC code : 24056 ...
Leukemia treatment options - Willamette Valley Cancer InstituteLeukemia treatment options - Willamette Valley Cancer Institute
It also may depend on certain features of the leukemia cells. Your doctor also considers your symptoms and general health.. People with acute leukemia need to be treated right away. The goal of treatment is to destroy signs of leukemia in the body and make symptoms go away. This is called a remission. After people go into remission, more therapy may be given to prevent a relapse. This type of therapy is called consolidation therapy or maintenance therapy. Many people with acute leukemia can be cured.. If you have chronic leukemia without symptoms, you may not need cancer treatment right away. Your doctor will watch your health closely so that treatment can start when you begin to have symptoms. Not getting cancer treatment right away is called active surveillance.. When treatment for chronic leukemia is needed, it can often control the disease and its symptoms. People may receive maintenance therapy to help keep the cancer in remission, but chronic leukemia can seldom be cured with chemotherapy. ...
Blood cancers (leukemia) - Kiadis PharmaBlood cancers (leukemia) - Kiadis Pharma
Leukemia is a cancer of the bone marrow and blood. The four major types of leukemia are acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL). Myelodisplastic syndrome (MDS) is a premalignant blood disorder that often develops into AML.. All leukemias originate in the bone marrow where a stem cell undergoes a mutation and becomes a leukemic cell. Once this leukemic cell mutates, it multiplies into billions of cells. These cells, called "leukemic blasts", do not function normally but grow and survive better than normal cells. The presence of the leukemic blasts blocks the production of normal white blood cells which are key for a proper functioning of the immune system. As a result, the number of healthy white blood cells is usually lower than normal, severely affecting a patients immunoprotection.. Acute leukemias (AML and ALL) are rapidly progressing diseases whereas chronic leukemias (CML and CLL) usually ...
Are Incidence Rates of Adult Leukemia in the United States Significantly Associated with Birth Cohort? | Cancer Epidemiology,...Are Incidence Rates of Adult Leukemia in the United States Significantly Associated with Birth Cohort? | Cancer Epidemiology,...
The 4 major leukemia types are established endpoints for descriptive (37) and analytic (38-41) epidemiologic studies; however, it is increasingly clear from molecular studies that these categories do not represent homogeneous groups of similar diseases but instead constitute heterogeneous groups of related diseases. Within the major types, the etiologies of the component diseases remain largely unclear and are very difficult to study because of the small numbers. For this reason, we and others have focused on the broad-based major types, recognizing that the mixing of subgroups might weaken or obscure any underlying association signals.. Therefore, it is quite striking to report that leukemia incidence varied significantly between birth cohorts for each major leukemia type in men and women except female AMLs; changes on the order of 1% per birth year or 20% per generation were observed. Our results are consistent with the hypothesis that many leukemia risks among adults are substantially ...
9/11 Leukemia Blood Cancer - 911 Cancer Claims9/11 Leukemia Blood Cancer - 911 Cancer Claims
Leukemia, like lymphoma and multiple myeloma, is a cancer of the blood and bone marrow and is one of the most common cancers among 9/11 responders and survivors. Turley Hansen has represented many claimants with leukemia since cancer was added to the list of illnesses covered under the Zadroga Act.. Leukemia begins in cells in the bone marrow. Over time, the leukemia cancer cells suppress the development of normal cells. There are different types of leukemia, and the rate at which leukemia develops and how the cells replace the normal blood and marrow cells are different with each type of leukemia. Types of leukemia include:. ...
Leukemia Quiz: What is Leukemia? Learn Symptoms SignsLeukemia Quiz: What is Leukemia? Learn Symptoms Signs
What is leukemia? What are the symptoms and signs of leukemia? What is the leukemia survival rate? Learn about acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, and other types of leukemia.
93 Percent Of Advanced Leukemia Patients In Remission After Immunotherapy93 Percent Of Advanced Leukemia Patients In Remission After Immunotherapy
Diagnosed with leukemia this year 2010, she experienced treatment that put her in remission, only to have her cancers come back a year . 5 later, more stubborn
Overcoming drug resistance offers new hope on leukemia -- Vector blogOvercoming drug resistance offers new hope on leukemia -- Vector blog
Gutierrez hopes this discovery will lower resistance to asparaginase among the children who come to Dana-Farber/Boston Childrens with leukemia. Beyond that, he believes his teams approach will inspire other researchers to seek out the causes of resistance to other leukemia drugs, with each new discovery improving the odds of survival for patients not helped by current therapies.. The discovery may also offer a less toxic alternative to leukemia patients who are cured by current treatments. Thats important because some leukemia drugs can have serious side effects decades later. "Sometimes youll get through this whole thing, your leukemia will be cured, and then five, ten, 20 years later youll have a late effect - heart failure, for example," Gutierrez says. "So for patients who are cured, I hope this will actually be able to replace some of the most toxic elements of standard therapy.". Finally, Gutierrez notes that the team doesnt fully understand why the two-drug treatment hits leukemia ...
Leukemia FAQ: What is Leukemia? | RxWikiLeukemia FAQ: What is Leukemia? | RxWiki
Leukemia is a cancer of the blood cells that most commonly occurs in adults older than 55. Additionally, leukemia is the most common cancer in children younger than 15. Leukemia typically involves white blood cells, which are the bodys natural defense against infection. However, the type of leukemia a patient develops depends on which blood cells become cancerous. In healthy people, white blood cells grow and divide in an orderly fashion as needed. But in patients with leukemia, the white blood cells produced are abnormal and dont function properly. Leukemia can be either acute (fast growing) or chronic (slower growing). There are currently more than 300,000 people estimated to be living with or in remission (signs of disease disappear) from leukemia in the US.
Take My Chronic Leukemia Exam - Do My Chronic Leukemia ExamTake My Chronic Leukemia Exam - Do My Chronic Leukemia Exam
we offer best Chronic Leukemia examination. We allow take my Chronic Leukemia examination for me. Our solutions are economical as well as 100% satisfactory. We have specialist specialists to try tests for you.
Gene therapy may provide hope for patients with advanced leukemia - Stop Cancer FundGene therapy may provide hope for patients with advanced leukemia - Stop Cancer Fund
There are two promising new treatments, but more research is needed before doctors will know more about which patients are most likely to benefit and before these treatments will be widely available.. Researchers at two hospitals in Philadelphia used an experimental treatment for ALL on 25 children and 5 adults.1 The children were seen at Childrens Hospital of Philadelphia by Dr. Shannon Maude and Dr. Stephan Grupp and their colleagues. The adult patients were treated at the University of Pennsylvania School of Medicine under the care of Dr. Noelle Frey. These patients all had relapsed several times or had failed to respond to any treatment. All had only a few weeks or months to live. The scientists took blood from each patient and separated out the white blood cells. These cancerous white blood cells were then genetically modified so that they could recognize and attack the diseased cells that cause the leukemia. The genetically modified cells were then put back in the patient using a blood ...
Leukemia Essay, Leukemia Research papersLeukemia Essay, Leukemia Research papers
250.000 FREE Leukemia Papers & Leukemia Essays at #1 ESSAYS BANK since 1998! BIGGEST and the BEST ESSAYS BANK. Leukemia Essays, Leukemia PAPERS, Courseworks, Leukemia Term Papers, Leukemia Research Papers and unique Leukemia papers from EssaysBank.com
Leukemia Symptoms, Causes, Treatment, Types & Survival RateLeukemia Symptoms, Causes, Treatment, Types & Survival Rate
Leukemia is cancer of the blood cells. Get the facts on leukemia (cancer of the bone marrow, blood) symptoms, survival rates, diagnosis, causes, signs, types (acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and chronic myeloid leukemia), research, treatment information, prognosis, and side effects.
Small molecule XIAP inhibitors sensitize childhood acute leukemia cells for CD95-induced apoptosisSmall molecule XIAP inhibitors sensitize childhood acute leukemia cells for CD95-induced apoptosis
apoptosis; XIAP; leukemia; CD95; acute lymphoblastic-leukemia; bone-marrow-transplantation; acute myeloid-leukemia; trail-induced apoptosis; cd95 apo-1/fas; t-cells; hematological malignancies; lymphocytic-leukemia; monoclonal-antibody; mediated ...
Leukemia Center by MedicineNet.comLeukemia Center by MedicineNet.com
Leukemia is cancer of the blood cells. Get the facts on leukemia (cancer of the bone marrow, blood) symptoms, survival rates, diagnosis, causes, signs, types (acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and chronic myeloid leukemia), research, treatment information, prognosis, and side effects.
St. Lukes - LeukemiaSt. Luke's - Leukemia
There are four types of leukemia. Two types, acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML), are categorized as acute because they spread quickly. With these types of leukemia, cancerous cells replace normal white blood cells that fight infection, red blood cells that carry oxygen to the body, and platelets that help blood clot.. The other two types, chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML), are classified as chronic, meaning they develop and progress gradually. When cancerous cells replace healthy cells, the body is susceptible to other adverse health effects such as infection, bleeding and anemia.. In any form of leukemia, cancerous cells replacing the healthy blood cells increase the bodys susceptibility to infection.. Close. ...
Leukemia in ChildrenLeukemia in Children
Leukemia is the most common cancer in children and teens, accounting for almost 1 out of 3 cancers. Most childhood leukemias are acute lymphocytic leukemia (ALL). Most of the remaining cases are acute myeloid leukemia (AML). Chronic leukemias are rare in children.
Leukemia News, Research - Page 2Leukemia News, Research - Page 2
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia dont become apparent until a large number of normal blood cells are crowded out by leukemia cells ...
Leukemia News, Research - Page 4Leukemia News, Research - Page 4
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia dont become apparent until a large number of normal blood cells are crowded out by leukemia cells ...
Leukemia: Causes, Symptoms and Treatment - LoperOnline.comLeukemia: Causes, Symptoms and Treatment - LoperOnline.com
Indonesia. We know together that Leukemia is one of the deadliest diseases, below we will talk about the Causes, Traits, and Treatment of Leukemia.. Leukemia is a type of cancer that affects the blood and bone marrow. Leukemia begins in cells in the bone marrow. Cells undergo changes and become a type of leukemia cell. Once marrow cells undergo leukemia changes, leukemia cells can grow and survive better than normal cells.. ...
Childhood Leukemia Survival RatesChildhood Leukemia Survival Rates
Survival rates of childhood leukemia are based on outcomes of people whove had the disease. Find the survival rates for childhood leukemia here.
Types of LeukemiaTypes of Leukemia
The types of leukemia also can be grouped based on the type of white blood cell that is affected. Leukemia can start in lymphoid cells or myeloid cells. Leukemia that affects lymphoid cells is called lymphoid, lymphocytic, or lymphoblastic leukemia. Leukemia that affects myeloid cells is called myeloid, myelogenous, or myeloblastic leukemia.. There are four common types of leukemia:. ...
AID 43233 - The compound was evaluated for antitumoral activity against human leukemia cell line CCRF CEM after 72 hr of...AID 43233 - The compound was evaluated for antitumoral activity against human leukemia cell line CCRF CEM after 72 hr of...
BioAssay record AID 43233 submitted by ChEMBL: The compound was evaluated for antitumoral activity against human leukemia cell line CCRF CEM after 72 hr of incubation.
Researchers Find Compelling Preclinical Evidence for High-Risk Leukemia Therapies | Bench to Bedside | CHOP Research InstituteResearchers Find Compelling Preclinical Evidence for High-Risk Leukemia Therapies | Bench to Bedside | CHOP Research Institute
If there is some small bright spot in getting a diagnosis of childhood cancer, it is that acute lymphoblastic leukemia (ALL), the most common form of leukemia in children, has one of the highest cure rates of all childhood cancers. Yet families may struggle to see that bright spot if they learn that their childs ALL is in the genetic subgroup known as Philadelphia-like B-cell lymphoblastic leukemia (Ph-like ALL), named for the disease biologys similarity to cancers caused by the famous Philadelphia chromosome mutation.. Although Ph-like ALL was first thought to be a rare subset of ALL cases, it is now known to account for 10 to 20 percent of B-cell ALL occurring in children and adolescents and nearly 30 percent of the disease in young adults. Patients with Ph-like ALL have a very high risk of relapse and poor responses to usual chemotherapy. After relapse, the prognosis for ALL is dim.. Researchers at Childrens Hospital of Philadelphia are working to restore the bright light of hope for ...
Peripheral retinal microaneurysms in chronic leukemia<...Peripheral retinal microaneurysms in chronic leukemia<...
TY - JOUR. T1 - Peripheral retinal microaneurysms in chronic leukemia. AU - Jampol, Lee M.. AU - Goldberg, Morton F.. AU - Busse, Bruce. PY - 1975/8. Y1 - 1975/8. N2 - Of 25 patients with chronic leukemia, there was clinical evidence of peripheral retinal microaneurysm formation in two of eight patients with chronic lymphocytic leukemia and six of 17 patients with chronic myelogenous leukemia. There was no proliferative retinopathy in any of the 25 patients. An elevated leukocyte count seemed necessary for microaneurysm formation in leukemia, although some patients with elevated counts had no microaneurysms. The prolonged leukocytosis of chronic leukemia can produce peripheral capillary dropout, vascular stagnation, microaneurysm formation, and, rarely, peripheral proliferative retinopathy similar to sickle cell disease.. AB - Of 25 patients with chronic leukemia, there was clinical evidence of peripheral retinal microaneurysm formation in two of eight patients with chronic lymphocytic leukemia ...
Hematologic Neoplasms; Hematologic Malignancies; Hematopoietic NeoplasmsHematologic Neoplasms; Hematologic Malignancies; Hematopoietic Neoplasms
... On-line free medical diagnosis assistant. Ranked list of possible diseases from either several symptoms or a full patient history. A similarity measure between symptoms and diseases is provided.
Acute Leukaemia | definition of Acute Leukaemia by Medical dictionaryAcute Leukaemia | definition of Acute Leukaemia by Medical dictionary
Looking for online definition of Acute Leukaemia in the Medical Dictionary? Acute Leukaemia explanation free. What is Acute Leukaemia? Meaning of Acute Leukaemia medical term. What does Acute Leukaemia mean?
A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from TACL consortium | Blood JournalA phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from TACL consortium | Blood Journal
Growing evidence indicates that aberrant DNA hypermethylation is associated with leukemogenesis, chemotherapy resistance, and relapse. DNA methyltransferase inhibitors such as azacitidine and decitabine have been shown to reverse drug resistance and prime leukemia cells to cytotoxic agents in vitro. Here we report the first pediatric phase 1 study using azacitidine in sequence with chemotherapy in patients with relapsed/refractory leukemia. Fourteen patients were enrolled, twelve with acute myeloid leukemia (AML) and two with acute lymphoblastic leukemia (ALL). All patients received azacitidine 75mg/m2/day subcutaneously for 5 days, followed by fludarabine 30mg/m2/day and cytarabine 2gm/m2/day intravenously for 5 days. The median number of prior regimens was 2 (range 1-5). Toxicities were typical of intensive chemotherapy. Febrile neutropenia and infection were the most common non-hematologic toxicities. No patients experienced dose-limiting toxicity. Seven of twelve AML patients achieved ...
Plasma membrane resident glucocorticoid receptors in cells from human leukemic patients and the CCRF-CEM cell line: Clinical...Plasma membrane resident glucocorticoid receptors in cells from human leukemic patients and the CCRF-CEM cell line: Clinical...
TY - CHAP. T1 - Plasma membrane resident glucocorticoid receptors in cells from human leukemic patients and the CCRF-CEM cell line: Clinical Implications. AU - Gametchu, Bahiru. AU - Watson, Cheryl. PY - 1995. Y1 - 1995. M3 - Chapter (peer-reviewed). SP - 163. EP - 176. BT - Glucocorticoid Receptor Structure and Leukemic Cell Responses. PB - Landes Bioscience. ER - ...
Sequential changes in platelet function and coagulation in leukemic children treated with L-asparaginase, prednisone, and...Sequential changes in platelet function and coagulation in leukemic children treated with L-asparaginase, prednisone, and...
TY - JOUR. T1 - Sequential changes in platelet function and coagulation in leukemic children treated with L-asparaginase, prednisone, and vincristine. AU - Pui, C. H.. AU - Jackson, C. W.. AU - Chesney, C.. AU - Lyles, S. A.. AU - Bowman, W. P.. AU - Abromowitch, M.. AU - Simone, J. V.. PY - 1983/1/1. Y1 - 1983/1/1. UR - http://www.scopus.com/inward/record.url?scp=0021014939&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0021014939&partnerID=8YFLogxK. U2 - 10.1200/JCO.1983.1.6.380. DO - 10.1200/JCO.1983.1.6.380. M3 - Article. C2 - 6583320. AN - SCOPUS:0021014939. VL - 1. SP - 380. EP - 385. JO - Journal of Clinical Oncology. JF - Journal of Clinical Oncology. SN - 0732-183X. IS - 6. ER - ...
Plus itPlus it
Fucosyltransferase (FT) activity of normal lymphocytes, normal granulocytes, and various types of human leukemic cells and electrofocusing pattern of FT activity in human leukemic cells and normal lymphocytes were examined using asialofetuin as an acceptor. Levels of FT activity in normal lymphocytes were higher than those of normal granulocytes in which FT activity was almost undetectable. The FT activity was higher in blast cells of acute myeloblastic leukemia and chronic myelogenous leukemia in blast crisis than in blast cells of acute lymphoblastic leukemia and the chronic phase of chronic myelogenous leukemia. The level of FT activity was lower in cells of chronic lymphocytic leukemia than that of normal lymphocytes, but it was higher than that of normal granulocytes. Three main isoelectric forms of FT in leukemic blast cells were identified by isoelectrofocusing, and they each had a characteristic focusing point: around pH 4.5 (peak 1); pH 4.9 (peak 2); and pH 5.2 (peak 3). In blast cells ...
Study finds new genetic defects in high-risk childhood leukemia subtypes with chromosomal lossStudy finds new genetic defects in high-risk childhood leukemia subtypes with chromosomal loss
Research led by St. Jude Childrens Research Hospital scientists has identified a possible lead in treatment of two childhood leukemia subtypes known for their dramatic loss of chromosomes and poor treatment outcomes.
Plus itPlus it
This study was conducted to characterize the activity of PPARγ nuclear receptor signaling pathway in leukemia cells. Leukemic cell lines showed high expression of PPARγ protein in both myeloid and lymphoid cells including Hodgkins disease and multiple myeloma cells. Although the presence of PPARγ has been reported in leukemic cell lines (44, 54, 55), we report here the frequent expression of PPARγ in primary leukemia samples including AML and CLL. PPARγ mRNA expression in primary AML was highest in myelomonocytic AML (M4) subtypes. These data suggest that CDDO and other PPARγ ligands might be particularly useful in the treatment of myelomonocytic subtypes of AML/myelodysplastic syndrome. This was also noted in a recent clinical trial in which PPARγ ligands exerted antileukemia activity in patients with chronic myelomonocytic leukemia (56).. It has been reported that PPARγ ligands can induce leukemic cells to differentiate toward macrophages (44, 57). In our study, 15-d-PGJ2, BRL49653, ...
Childhood leukemia statistics - Canadian Cancer SocietyChildhood leukemia statistics - Canadian Cancer Society
Childhood leukemia is the most common cancer diagnosed in Canadian children. Learn about childhood leukemia incidence and mortality statistics.
Childhood leukemia statistics - Canadian Cancer SocietyChildhood leukemia statistics - Canadian Cancer Society
Childhood leukemia is the most common cancer diagnosed in Canadian children. Learn about childhood leukemia incidence and mortality statistics.
Researchers Develop New Potential Drug for Rare Leukemia; Separate Study Suggests Possible Role in Prostate Cancer Treatment -...Researchers Develop New Potential Drug for Rare Leukemia; Separate Study Suggests Possible Role in Prostate Cancer Treatment -...
Researchers Develop New Potential Drug for Rare Leukemia; Separate Study Suggests Possible Role in Prostate Cancer Treatment ANN ARBOR, Mich. - Researchers at the University of Michigan have developed a new drug candidate that shows potential in laboratory studies against a rare type of acute leukemia. Additional studies suggest the same compound could play a role in prostate cancer treatment as well.. The compound was developed in the labs of Jolanta Grembecka, Ph.D., and Tomasz Cierpicki, Ph.D., who have been working for several years to identify a small-molecule inhibitor that would block the interaction between the protein menin and MLL fusion proteins that cause a rare type of acute leukemia.. So-called MLL fusion leukemia can occur in both adults and children. It represents up to 10 percent of acute leukemia in adults, and about 70 percent of acute leukemia in infants. Current treatments are not very effective, with just over a third of patients surviving five years.. Protein-protein ...
Fasting could help treat most common childhood leukemia | Touch Latest Local,World,Tech,Entertainment,Health,Sport NewsFasting could help treat most common childhood leukemia | Touch Latest Local,World,Tech,Entertainment,Health,Sport News
Intermittent fasting may help combat the most common type of childhood leukemia - acute lymphoblastic leukemia - according to new research published in the journal Nature Medicine.Acute lymphoblastic leukemia (ALL), also called acute lymphocytic leukemia, is a cancer that begins in immature versions of white blood cells in the bone marrow, called lymphocytes.. There are two types of ALL: B cell ALL, which begins in the B lymphocytes (B cells), and T cell ALL, which begins in the T lymphocytes (T cells).. ALL stops B cells and T cells from maturing. As a result, large numbers of immature, leukemic cells are released into the bloodstream, outweighing the number of healthy white blood cells, red blood cells, and platelets.. The reduction in healthy white blood cells makes a patient vulnerable to infection, while low levels of platelets and red blood cells can lead to unusual bleeding and anemia. Other signs and symptoms of ALL include fatigue, loss of appetite, fever, rib pain, and bone or joint ...
Banding in leukemia: Techniques and implications<...Banding in leukemia: Techniques and implications<...
TY - JOUR. T1 - Banding in leukemia. T2 - Techniques and implications. AU - Whang-Peng, J.. PY - 1979/1/1. Y1 - 1979/1/1. N2 - The presence of the Ph1 chromosome in the hematopoietic cells of individuals with apparent hematologic disorders is virtually diagnostic of CML. In patients without any hematologic or clinical symptoms, the presence of the Ph1 chromosome can be an indicator of the preleukemic state. Published data in cytogenetic studies of acute leukemia hae shown that approximately half the patients exhibit chromosomal abnormalities in their bone marrow. Rowley and Potter reviewed the available banding data for acute nonlymphocytic leukemia and noted that the incidence of chromosomally abnormal patients was underestimated by at least 10-20%. They found various nonrandom chromosome changes including an additional #8 chromosome, the loss of chromosome #7, a gain or loss of #21, frequent structural rearrangements of #8 and 21, and the loss of a sex chromosome. Less banding data are ...
Loss of Usp18 Impairs the Propagation of Myeloid Leukemia Cells in Mouse ModelsLoss of Usp18 Impairs the Propagation of Myeloid Leukemia Cells in Mouse Models
Author(s): Zhang, Yue | Advisor(s): Zhang, Dong-Er | Abstract: Acute Myloid Leukemia (AML) is one of the most common leukemia in adults with poor five years survival even with modern chemotherapy treatment. New strategies need to be developed in order to enhance the survival of AML patients. Interferon-α (IFN-α), a type I IFN, is a known as an anti-tumor agent, which used to clinical treat AML because of its anti-proliferative effect and immune response. However, the clinical trials show divergent results because of the instability and delivery difficulty. USP18 is a negative regulator of Type I IFN signaling pathway. Knockout Usp18 can enhance and prolong the Type I IFN pathway. Here, we use AE9a-included leukemia mouse models that reflect the genetics and pathology of human acute myeloid leukemia to study the effect of Usp18 loss in leukemia development and to discover possible new therapeutic targets for leukemia. Results show that deletion of Usp18 delayed leukemia propagation in both the AE9a
Smoking and risk of leukemia | RTISmoking and risk of leukemia | RTI
The relation between tobacco use and leukemia was evaluated in a population-based case-control study of 578 white men with leukemia and 820 controls conducted in Iowa and Minnesota during 1981-1984. Risks were significantly elevated for all leukemia (odds ratio (OR) = 1.4) and chronic lymphocytic leukemia (OR = 1.6) for both tobacco users and cigarette smokers. There were significantly elevated risks for cigarette smokers of longest duration for all leukemia (OR = 1.6), chronic myelogenous leukemia (OR = 3.3), and chronic lymphocytic leukemia (OR = 1.6).
A NOVEL CELL SURFACE ANTIGEN (T305) FOUND IN INCREASED FREQUENCY ON ACUTE LEUKEMIA CELLS AND IN AUTOIMMUNE DISEASE STATES -...A NOVEL CELL SURFACE ANTIGEN (T305) FOUND IN INCREASED FREQUENCY ON ACUTE LEUKEMIA CELLS AND IN AUTOIMMUNE DISEASE STATES -...
O:13:PanistOpenUrl:36:{s:10:\u0000*\u0000openUrl;N;s:6:\u0000*\u0000idc;N;s:6:\u0000*\u0000fmt;s:7:journal;s:6:\u0000*\u0000doi;s:0:;s:6:\u0000*\u0000pii;s:0:;s:7:\u0000*\u0000pmid;s:0:;s:9:\u0000*\u0000atitle;s:121:A NOVEL CELL SURFACE ANTIGEN (T305) FOUND IN INCREASED FREQUENCY ON ACUTE LEUKEMIA CELLS AND IN AUTOIMMUNE DISEASE STATES;s:9:\u0000*\u0000jtitle;s:0:;s:9:\u0000*\u0000stitle;s:0:;s:7:\u0000*\u0000date;s:4:1983;s:9:\u0000*\u0000volume;s:0:;s:8:\u0000*\u0000issue;s:0:;s:8:\u0000*\u0000spage;s:0:;s:8:\u0000*\u0000epage;s:0:;s:8:\u0000*\u0000pages;s:0:;s:7:\u0000*\u0000issn;s:0:;s:8:\u0000*\u0000eissn;s:0:;s:9:\u0000*\u0000aulast;s:3:FOX;s:10:\u0000*\u0000aufirst;s:2:RI;s:9:\u0000*\u0000auinit;N;s:10:\u0000*\u0000auinitm;N;s:5:\u0000*\u0000au;a:7:{i:0;s:6:FOX RI;i:1;s:10:HUENIKEN M;i:2;s:6:FONG S;i:3;s:7:BEHAR ...
Next-Gen Sequencing in the Evaluation of Hematologic NeoplasmsNext-Gen Sequencing in the Evaluation of Hematologic Neoplasms
How might next-generation sequencing be utilized effectively for the screening, diagnosis, and follow-up of hematologic neoplasms?
Pathways linking treatment intensity and psychosocial outcomes among adult survivors of childhood leukemia<...Pathways linking treatment intensity and psychosocial outcomes among adult survivors of childhood leukemia<...
TY - JOUR. T1 - Pathways linking treatment intensity and psychosocial outcomes among adult survivors of childhood leukemia. AU - Chen, Edith. AU - Zeltzer, Lonnie K.. AU - Bentler, Peter M.. AU - Byrne, Julianne. AU - Nicholson, H. Stacy. AU - Meadows, Anna T.. AU - Mills, James L.. AU - Haupt, Riccardo. AU - Fears, Thomas R.. AU - Robison, Leslie L.. PY - 1998. Y1 - 1998. N2 - To determine the pathways between treatment intensity (age at diagnosis, dosage of chemotherapy [intrathecal methotrexate; IT-MTX] and cranial radiation [CRT]) and various psychosocial outcomes, review of medical records and structured interviews were carried out in 510 adult survivors of childhood leukemia. Structural equation modeling revealed that higher treatment intensity during childhood (indicated by treatment with high-dose CRT, low-dose IT-MTX, and adjusted by younger age at diagnosis) predicted more health-compromising behaviors as adults through lower educational achievement. Additionally, higher childhood ...
JCI - CD19 CAR T cell product and disease attributes predict leukemia remission durabilityJCI - CD19 CAR T cell product and disease attributes predict leukemia remission durability
BACKGROUND. Chimeric antigen receptor (CAR) T cells can induce remission in highly refractory leukemia and lymphoma subjects, yet the parameters for achieving sustained relapse-free survival are not fully delineated. METHODS. We analyzed 43 pediatric and young adult subjects participating in a phase I trial of defined composition CD19 CAR T cells (ClinicalTrials.gov, NCT02028455). CAR T cell phenotype, function, and expansion, as well as starting material T cell repertoire, were analyzed in relationship to therapeutic outcome (defined as achieving complete remission within 63 days) and duration of leukemia-free survival and B cell aplasia. RESULTS. These analyses reveal that initial therapeutic failures (n = 5) were associated with attenuated CAR T cell expansion and/or rapid attrition of functional CAR effector cells following adoptive transfer. The CAR T products were similar in phenotype and function when compared with products resulting in sustained remissions. However, the initial apheresed ...
Therapy‐related leukemia. A panmyelosis<...Therapy‐related leukemia. A panmyelosis<...
TY - JOUR. T1 - Therapy‐related leukemia. A panmyelosis. AU - Foucar, Kathy. AU - McKenna, Robert W.. AU - Bloomfield, Clara D.. AU - Bowers, Timothy K.. AU - Brunning, Richard D.. PY - 1979/4. Y1 - 1979/4. N2 - Fifteen patients developed acute nonlymphocytic leukemia (ANLL) 31 to 182 months following chemotherapy and/or radiotherapy for various malignancies and one non‐neoplastic disorder. The ANLL was commonly heralded by a brief preleukemic phase consisting of cytopenias and a variety of morphologic abnormalities. At diagnosis of ANLL, all of the patients had a panmyelosis with variation in the predominant abnormal cell line. Neutrophilic and erythroid abnormalities were most striking in 12 of the patients, megakaryocytic abnormalities predominated in 2 and monocytic abnormalities in 1. Pancytopenia, marked anisopoikilocytosis, normoblastemia, large hypogranular platelets, hypogranular neutrophils, pseudo‐Pelger‐Huet nuclei, low myeloblast counts and basophilia were the most common ...
Cancer and Healty Center: Types of LeukemiaCancer and Healty Center: Types of Leukemia
Hairy cell leukemia was a type that was rare from chronic leukemia. Article this did not do business with hairy cell leukemia or types that were rare from leukemia. Together, these rare leukemia were responsible to approximately 5.200 new cases from leukemia every year ...
CYTARABINE - FOR INTRAVENOUS, INTRATHECAL AND SUBCUTANEOUS USE ONLY (cytarabine injection) Indications and Usage | Pfizer...CYTARABINE - FOR INTRAVENOUS, INTRATHECAL AND SUBCUTANEOUS USE ONLY (cytarabine injection) Indications and Usage | Pfizer...
Cytarabine Injection in combination with other approved anti-cancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and pediatric patients. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration of Cytarabine Injection (preservative free preparations only) is indicated in the prophylaxis and treatment of meningeal leukemia. ...
Leukemia | VJHemOncLeukemia | VJHemOnc
Leukemia represents around 3.7% of all new cancer cases and 4.1% of cancer-related deaths in the US, and around 3% of new cancer cases and cancer-associated mortality in the UK. The NIH reports that 60.6% of people survive 5 years or more after a diagnosis of leukemia (based on data from SEER 18 2007-2013). The causes of leukemia are not fully understood, although a variety of genetic, epigenetic and environmental factors are thought to serve a role. Smoking, ionizing radiation, certain chemicals and prior chemotherapy have all been associated with leukemogeneis. Since the early 1990s, the incidence rates of leukemia have gradually increased, for which many reasons could be speculated.. Treatment usually comprises a combination of standard chemotherapy, radiotherapy, targeted therapy and bone marrow transplant. Exciting novel therapies for the treatment of leukemias are being researched, including immunotherapies, such as CAR T-cells and bispecific antibodies, in addition to novel combination ...
Late Effects Tracker: Johns Hopkins Leukemia Survivors ProgramLate Effects Tracker: Johns Hopkins Leukemia Survivors Program
The most common late and long-term effects of leukemia and leukemia therapy are related to the kind of cancer you had or the specific treatments you received. Late effects often occur because the treatments used to kill cancer cells can sometimes damage or kill healthy cells.. To find out more about the most common late effects among childhood and adult leukemia survivors, you can search our Late Effects Tracker by common leukemia type or by treatment.. Search By: ...
Update on Leukemia Patient Molly CampbellUpdate on Leukemia Patient Molly Campbell
Little Molly Campbell has cleared the first hurdle in her treatment.. Weve been following her journey since she was diagnosed with Acute Lymphoblastic Leukemia on Christmas Eve last year.. The three-month-old, began her first round of chemotherapy in early January. That stage of treatment has been completed and her most recent tests show her to be in clinical remission.. Clinical remission is defined by a benchmark occurring when less than five percent of the cells, produced by the patients bone marrow, are leukemia cells. Mollys bone marrow is currently producing three percent leukemia cells.. Paul Pearson, a friend and spokesperson for the family says, "It means she has a chance to survive. What it means is its cleared the way for stronger chemotherapy drugs.". Molly was essentially a newborn when she was diagnosed. She is a very young child, fighting a very rare form of leukemia. Her condition is difficult to treat and her unusually young age makes her situation even more precarious, as ...
Lisette for the Leukemia & Lymphomas Woman of the Year Award | Stephen Harrisons FundraiserLisette for the Leukemia & Lymphoma's Woman of the Year Award | Stephen Harrison's Fundraiser
I am campaigning on behalf of a very special 15 year old girl who is campaigning to become the Leukemia & Lymphoma Societys Woman of the Year. The mission of the Leukemia & Lymphoma Society is to cure leukemia, lymphoma, Hodgkins disease and myeloma, and improve the quality of life of patients and their families. Man & Woman of the Year is national campaign to with a goal of raising over one million dollars to that end this year. The very special 15 years old I am referring to is Lisette Watters. When Lisette was only 4 years old, her younger sister Caroline was diagnosed with Acute Mylogenous Leukemia, and Carolines best chance of survival was to get a bone marrow transplant. It turned out that Lisette was a perfect match for her sister, and this brave little girl donated her marrow, saving her sisters life. Now, 11 years later, Lisette is campaigning for the Leukemia & Lymphoma Societys Woman of the Year. So I am encouraging you today to donate to Lisettes campaign and help make her the
E3993 - Archived Educational Materials - ECOG-ACRINE3993 - Archived Educational Materials - ECOG-ACRIN
Title. Comparing Three Standard Treatments in Older Adult Patients with Acute Non-Lymphocytic Leukemia and Studying the Effect of GM-CSF to See Whether It May Improve Initial Response to Chemotherapy (A Phase III Trial). Sponsor. Eastern Cooperative Oncology Group through the NCI-sponsored Cancer Cooperative Group Program. Purpose of the Study. To determine whether one of three chemotherapy drugs (daunorubicine, idarubicin and mitoxantrone) is superior when used in the treatment of acute non-lymphocytic leukemia in adults over age 55 and to see whether receiving GM-CSF, a stimulator of blood cell production in the bone marrow, before the start of treatment can improve a patients response to chemotherapy.. Results. No difference was observed in the complete response rate (the disappearance of signs of cancer in response to treatment) among the three drugs studied. Patients who received GM-CSF before the chemotherapy did not show improved response to therapy compared with placebo. Patients who ...
Two consecutive immunophenotypic switches in a child with MLL-rearranged acute lymphoblastic leukemia | HaematologicaTwo consecutive immunophenotypic switches in a child with MLL-rearranged acute lymphoblastic leukemia | Haematologica
An 18-month-old girl was diagnosed with pre-pre-B ALL/t(4;11) leukemia, which during the treatment and after matched bone marrow transplantation (BMT), underwent two consecutive switches from lymphoid to myeloid lineage and vice versa. The high expression of HOXA9 and FLT3 genes remaining genotypically stable in a leukemia throughout phenotypic switches, suggests that this leukemia may have originated as a common B/myeloid progenitors.. ...
Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemiaPhosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia
The 8p11 myeloproliferative syndrome (EMS) is associated with translocations that disrupt the FGFR1 gene. To date, 8 fusion partners of FGFR1 have been identified. However, no primary leukemia cell lines were identified that contain any of these fusions. Here, we screened more than 40 acute myeloid …
Leukemia (for Parents) - Print Version - Aetna Better Health of Virginia (Medicaid)Leukemia (for Parents) - Print Version - Aetna Better Health of Virginia (Medicaid)
Leukemia is cancer of the white blood cells. White blood cells (also called leukocytes or WBCs) fight infections and other diseases.. In leukemia, the bone marrow (spongy material inside the bones) makes many white blood cells that arent normal. These abnormal WBCs crowd the bone marrow and get into the bloodstream. Unlike healthy white blood cells, they cant protect the body from infections.. Sometimes leukemia (loo-KEE-mee-uh) spreads from the bone marrow to other parts of the body, like the chest, brain, or liver.. Leukemia is the most common type of cancer in children. But most kids and teens treated for leukemia are cured of the disease.. ...
What are typical symptoms of leukemia when diagnosed? - Answered by top doctors on HealthTapWhat are typical symptoms of leukemia when diagnosed? - Answered by top doctors on HealthTap
Dr. Ho responded: Which leukemia?. There are chronic and acute leukemia. Some symptoms related to acute leukemia may include fatigue, shortness of breath, fevers, chils, |a href="/topics/night-sweats" track_data="{
Children treated for acute lymphoblastic leukemia may grow up to have heart problems, study findsChildren treated for acute lymphoblastic leukemia may grow up to have heart problems, study finds
Acute lymphoblastic leukemia (ALL) is a type of cancer that affects the blood and bone marrow. It is the most common type of cancer developed by children. Although ALL is known to progress quickly, advances in modern medicine have increased the survival rate of children with this disease. However, a recent study by researchers from the Medical University […]
Application of the pMHC array to characterise tumour antigen specific T cell populations in leukaemia patients at disease...Application of the pMHC array to characterise tumour antigen specific T cell populations in leukaemia patients at disease...
Immunotherapy treatments for cancer are becoming increasingly successful, however to further improve our understanding of the T-cell recognition involved in effective responses and to encourage moves towards the development of personalised treatments for leukaemia immunotherapy, precise antigenic targets in individual patients have been identified. Cellular arrays using peptide-MHC (pMHC) tetramers allow the simultaneous detection of different antigen specific T-cell populations naturally circulating in patients and normal donors. We have developed the pMHC array to detect CD8+ T-cell populations in leukaemia patients that recognise epitopes within viral antigens (cytomegalovirus (CMV) and influenza (Flu)) and leukaemia antigens (including Per Arnt Sim domain 1 (PASD1), MelanA, Wilms Tumour (WT1) and tyrosinase). We show that the pMHC array is at least as sensitive as flow cytometry and has the potential to rapidly identify more than 40 specific T-cell populations in a small sample of T-cells ...
Complexes of platinum(II) or palladium(II) with 1,10-phenanthroline and amino acids | ScholarBank@NUSComplexes of platinum(II) or palladium(II) with 1,10-phenanthroline and amino acids | [email protected]
The amino acids complexes of [Pt(phen)(AA)]NO3·xH2O and [Pd(phen)(AA)]NO3·xH2O have been prepared by the interaction of palladium and platinum complexes, [Pt(phen)Cl2] and [Pd(phen)Cl2] with salts of amino acids in methanol and characterized by 1H NMR and IR spectroscopy which confirmed the formation of a very large variety of compounds with ligand in a simple way (bidentate). All of these new compounds have been isolated and tested for cytotoxicity on Molt-4, a human leukaemia cell line. The IC50 values of [Pt(phen)(Pro)]Cl·2H2O and [Pd(phen)(Asp)]Cl·1.5H2O are 9.8 and 7.31 μM, respectively, exhibiting a significant activity which is close to cis-[PtCl2(NH3)2]. (C) 2000 Elsevier Science S.A ...
Leukemia in Children: Care InstructionsLeukemia in Children: Care Instructions
Leukemia is a type of cancer of the blood cells. The body makes too many white blood cells, and the cells do not act normally. Over time they crowd out the normal blood cells. There are many different kinds of leukemia. The type of treatment your child receives depends on the type of leukemia he or she has.. Leukemia is usually treated with medicines, such as chemotherapy. Your child may also need radiation treatments or a procedure called a stem cell transplant. Your doctor will talk to you about what type of leukemia your child has and what kinds of treatment may be best for him or her.. When you find out that your child has cancer, you and your child may feel many emotions and may need some help coping. Seek out family, friends, and counsellors for support. You also can do things at home to make you and your child feel better while he or she goes through treatment. Call the Canadian Cancer Society (1-888-939-3333) or visit its website at www.cancer.ca for more information. ...
Items where Author is Pearson, A. D. - Northumbria Research LinkItems where Author is "Pearson, A. D." - Northumbria Research Link
Padget, Kay, Pearson, A. D. and Austin, Caroline (2000) Quantitation of DNA topoisomerase IIalpha and beta in human leukaemia cells by immunoblotting. Leukemia, 14 (11). pp. 1997-2005. ISSN 0887-6924 ...
Alexs Place - Update on Alexs Fight Against Acute Myelogenous LeukemiaAlex's Place - Update on Alex's Fight Against Acute Myelogenous Leukemia
Update on Alexandra Martinis fight against pediatric Acute Myelogenous Leukemia, with information, and links, on Childhood Cancer, Pediatric Leukemia, Cord Blood Transplants, & other Cancer Resources
BMF (gene)BMF (gene)
CD34CD34
CD79BCD79B
Enhancer of polycomb homolog 2 (drosophila)Enhancer of polycomb homolog 2 (drosophila)
SH3BP1SH3BP1
ELF2ELF2
Mir-708 microRNA precursor familyMir-708 microRNA precursor family
CereblonCereblon
Placenta specific 8Placenta specific 8
Plasma cell dyscrasiaPlasma cell dyscrasia
CUTL1CUTL1
TSC22D1TSC22D1
Cruciferous vegetablesCruciferous vegetables
RAP1BRAP1B
MicroRNAMicroRNA
Innate immune systemInnate immune system
HOXC4HOXC4
Elkhan ZeynalliElkhan Zeynalli
Nucleoside triphosphateNucleoside triphosphate
Development of analogs of thalidomideDevelopment of analogs of thalidomide
SMARCA4SMARCA4
HaptocorrinHaptocorrin
Granulocyte colony-stimulating factorGranulocyte colony-stimulating factor
NEDD8NEDD8
Fas ligandFas ligand
DOK1DOK1
CrenolanibCrenolanib
HSPA9HSPA9
AzacitidineAzacitidine
P21P21
AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsInformation ScienceHealth Care
LeukemiaLeukemia, Myeloid, AcuteLeukemia, Lymphocytic, Chronic, B-CellLeukemia, LymphoidLeukemia, ExperimentalLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia Virus, MurinePrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, T-CellLeukemia, Monocytic, AcuteMoloney murine leukemia virusLeukemia, Hairy CellLeukemia L1210Leukemia, B-CellLeukemia Virus, BovineLeukemia Virus, FelineGene Expression Regulation, LeukemicLeukemia, Radiation-InducedMyeloid-Lymphoid Leukemia ProteinLeukemia P388Leukemia, Biphenotypic, AcuteFriend murine leukemia virusHL-60 CellsLeukemia-Lymphoma, Adult T-CellCytarabineLeukemia, Megakaryoblastic, AcuteAKR murine leukemia virusFusion Proteins, bcr-ablLeukemia, Myeloid, Chronic-PhaseBone MarrowAcute DiseaseRemission InductionPrecursor B-Cell Lymphoblastic Leukemia-LymphomaAntineoplastic AgentsDaunorubicinTumor Cells, CulturedLeukemia, Plasma CellLeukemia, Myeloid, Accelerated PhaseKaryotypingK562 CellsLeukemia, Prolymphocytic, T-CellHuman T-lymphotropic virus 1Cell LineLeukemia, ProlymphocyticNeoplasm ProteinsCore Binding Factor Alpha 2 SubunitLeukemia, Myelomonocytic, JuvenilePrecursor T-Cell Lymphoblastic Leukemia-LymphomaLeukemia, Basophilic, AcuteBase SequenceLeukemic InfiltrationAsparaginasefms-Like Tyrosine Kinase 3Philadelphia ChromosomeLymphomaLeukemia, Myeloid, Chronic, Atypical, BCR-ABL NegativeMolecular Sequence DataApoptosisGraft vs Leukemia EffectAbelson murine leukemia virusChromosome AberrationsAntineoplastic Combined Chemotherapy ProtocolsLeukemia Inhibitory Factor Receptor alpha SubunitPreleukemiaPrognosisImmunophenotypingNeoplasm, ResidualBone Marrow TransplantationLeukemia, Large Granular LymphocyticCytogenetic AnalysisRetroviridaeCell DifferentiationDrug Resistance, NeoplasmRecurrenceFlow CytometryNeoplastic Stem CellsRetroviridae InfectionsHematopoietic Stem CellsCell Line, TumorOxidesGene Products, taxTreatment OutcomeMutationArsenicalsGene RearrangementIdarubicinVidarabineLeukemia Virus, Gibbon ApeDNA, NeoplasmChromosomes, Human, Pair 21Cell Transformation, NeoplasticTretinoinB-LymphocytesMyeloid Cell Leukemia Sequence 1 ProteinGenes, ablTranscription FactorsT-LymphocytesTransplantation, HomologousLeukemia, FelineCytogeneticsRNA, MessengerProto-Oncogene ProteinsCladribineChromosomes, Human, Pair 11Growth InhibitorsBurkitt LymphomaProto-OncogenesDisease-Free SurvivalCell DivisionPolymerase Chain ReactionDNA-Binding ProteinsHematopoietic Stem Cell TransplantationMice, Inbred AKRSurvival AnalysisEnzootic Bovine Leukosis6-MercaptopurineAntigens, NeoplasmAntibodies, MonoclonalRNA, NeoplasmMethotrexateTime FactorsAntigens, CDChromosomes, Human, 21-22 and YSurvival RateVincristineLeukemia, Mast-CellCell SurvivalClone CellsNuclear ProteinsNeoplasms, Second PrimaryReceptors, OSM-LIFReverse Transcriptase Polymerase Chain ReactionRadiation Leukemia VirusSialic Acid Binding Ig-like Lectin 3Leukemia, Neutrophilic, ChronicLymphocytesMice, SCIDThioguanineProtein Kinase InhibitorsProvirusesCells, CulturedAmino Acid SequenceGranulocytesSignal TransductionIn Situ Hybridization, FluorescenceAntimetabolites, AntineoplasticChromosomes, Human, Pair 8PentostatinDeltaretrovirusJurkat CellsDNA, ViralCell ProliferationTranscription, GeneticProto-Oncogene Proteins c-bcl-2Leukocyte CountDrug Screening Assays, AntitumorAntibiotics, AntineoplasticDose-Response Relationship, DrugGraft vs Host DiseaseTransfectionAntigens, CD34Myeloproliferative DisordersCyclophosphamideLeukemia, Prolymphocytic, B-CellEtoposideBlotting, SouthernOncogenesDeltaretrovirus InfectionsAntigens, SurfaceHematopoiesisChlorambucilGene Expression Regulation, NeoplasticChromosomes, Human, Pair 17Protein-Tyrosine KinasesDrug SynergismImmunoglobulin Heavy ChainsPhenotypeChromosomes, Human, Pair 12Neoplasm TransplantationChromosome DisordersArabinonucleosidesMitoxantroneGammaretrovirusHTLV-I InfectionsCombined Modality TherapyGenes, ViralMice, Inbred StrainsCell CycleProto-Oncogene Proteins c-bcrCell Transformation, ViralGene Expression ProfilingAntigens, CD38Tumor Suppressor ProteinsAntigens, CD19Gene ExpressionHarringtoninesRNA-Directed DNA PolymeraseRetrospective StudiesTumor Stem Cell AssayTumor Virus InfectionsAntibodies, Neoplasm
Leukemia Center by MedicineNet.comLeukemia Center by MedicineNet.com
Tracking down therapy-resistant leukemia cells | EurekAlert! Science NewsTracking down therapy-resistant leukemia cells | EurekAlert! Science News
Leukemia Symptoms, Causes, Treatment, Types & Survival RateLeukemia Symptoms, Causes, Treatment, Types & Survival Rate
URMC Finds Leukemia Cells Are Bad To The Bone - RedorbitURMC Finds Leukemia Cells Are "Bad To The Bone" - Redorbit
Leukemia Treatment, Diagnosis, Causes, Symptoms, PrognosisLeukemia Treatment, Diagnosis, Causes, Symptoms, Prognosis
Normal Blood and Marrow | Leukemia and Lymphoma SocietyNormal Blood and Marrow | Leukemia and Lymphoma Society
Patterns of chronic lymphocytic leukemia growth identified - Dana-Farber Cancer Institute | Boston, MAPatterns of chronic lymphocytic leukemia growth identified - Dana-Farber Cancer Institute | Boston, MA
The Leukemia & Lymphoma Society of Canada | Donate Today!The Leukemia & Lymphoma Society of Canada | Donate Today!
Chronic lymphocytic leukemia in young individuals revisited | HaematologicaChronic lymphocytic leukemia in young individuals revisited | Haematologica
LeukemiaLeukemia
LeukemiaLeukemia
Leukemia | CDCLeukemia | CDC
Leukemia - WikipediaLeukemia - Wikipedia
leukemialeukemia
LeukemiaLeukemia
Lymphoid leukemia - WikipediaLymphoid leukemia - Wikipedia
Leukemia | MedlinePlusLeukemia | MedlinePlus
leukemia - Baltimore Sunleukemia - Baltimore Sun
Childhood Leukemia | MedlinePlusChildhood Leukemia | MedlinePlus
Childhood Leukemia SubtypesChildhood Leukemia Subtypes
Treating Childhood LeukemiaTreating Childhood Leukemia
leukemia: Types | Infopleaseleukemia: Types | Infoplease
2008 Leukemia Cup Regatta - YouTube2008 Leukemia Cup Regatta - YouTube
Chronic Leukemia | Encyclopedia.comChronic Leukemia | Encyclopedia.com
Leukemia Explained With PicturesLeukemia Explained With Pictures
Neutropenic Enterocolitis in LeukemiaNeutropenic Enterocolitis in Leukemia
Leukemia: ALL vs. AMLLeukemia: ALL vs. AML
Unknown: Leukemia | Encyclopedia.comUnknown: Leukemia | Encyclopedia.com
Leukemia TreatmentLeukemia Treatment
Leukemia... anyone intrested..? | Yahoo AnswersLeukemia... anyone intrested..? | Yahoo Answers
Acute Myeloid LeukemiaAcute Myeloid Leukemia
Leukemia News, ResearchLeukemia News, Research
AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsInformation ScienceHealth Care
LeukemiaLeukemia, Myeloid, AcuteLeukemia, Lymphocytic, Chronic, B-CellLeukemia, LymphoidLeukemia, ExperimentalLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia Virus, MurinePrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, T-CellLeukemia, Monocytic, AcuteMoloney murine leukemia virusLeukemia, Hairy CellLeukemia L1210Leukemia, B-CellLeukemia Virus, BovineLeukemia Virus, FelineGene Expression Regulation, LeukemicLeukemia, Radiation-InducedMyeloid-Lymphoid Leukemia ProteinLeukemia P388Leukemia, Biphenotypic, AcuteFriend murine leukemia virusHL-60 CellsLeukemia-Lymphoma, Adult T-CellCytarabineLeukemia, Megakaryoblastic, AcuteAKR murine leukemia virusFusion Proteins, bcr-ablLeukemia, Myeloid, Chronic-PhaseBone MarrowAcute DiseaseRemission InductionPrecursor B-Cell Lymphoblastic Leukemia-LymphomaAntineoplastic AgentsDaunorubicinTumor Cells, CulturedLeukemia, Plasma CellLeukemia, Myeloid, Accelerated PhaseKaryotypingK562 CellsLeukemia, Prolymphocytic, T-CellHuman T-lymphotropic virus 1Cell LineLeukemia, ProlymphocyticNeoplasm ProteinsCore Binding Factor Alpha 2 SubunitLeukemia, Myelomonocytic, JuvenilePrecursor T-Cell Lymphoblastic Leukemia-LymphomaLeukemia, Basophilic, AcuteBase SequenceLeukemic InfiltrationAsparaginasefms-Like Tyrosine Kinase 3Philadelphia ChromosomeLymphomaLeukemia, Myeloid, Chronic, Atypical, BCR-ABL NegativeMolecular Sequence DataApoptosisGraft vs Leukemia EffectAbelson murine leukemia virusChromosome AberrationsAntineoplastic Combined Chemotherapy ProtocolsLeukemia Inhibitory Factor Receptor alpha SubunitPreleukemiaPrognosisImmunophenotypingNeoplasm, ResidualBone Marrow TransplantationLeukemia, Large Granular LymphocyticCytogenetic AnalysisRetroviridaeCell DifferentiationDrug Resistance, NeoplasmRecurrenceFlow CytometryNeoplastic Stem CellsRetroviridae InfectionsHematopoietic Stem CellsCell Line, TumorOxidesGene Products, taxTreatment OutcomeMutationArsenicalsGene RearrangementIdarubicinVidarabineLeukemia Virus, Gibbon ApeDNA, NeoplasmChromosomes, Human, Pair 21Cell Transformation, NeoplasticTretinoinB-LymphocytesMyeloid Cell Leukemia Sequence 1 ProteinGenes, ablTranscription FactorsT-LymphocytesTransplantation, HomologousLeukemia, FelineCytogeneticsRNA, MessengerProto-Oncogene ProteinsCladribineChromosomes, Human, Pair 11Growth InhibitorsBurkitt LymphomaProto-OncogenesDisease-Free SurvivalCell DivisionPolymerase Chain ReactionDNA-Binding ProteinsHematopoietic Stem Cell TransplantationMice, Inbred AKRSurvival AnalysisEnzootic Bovine Leukosis6-MercaptopurineAntigens, NeoplasmAntibodies, MonoclonalRNA, NeoplasmMethotrexateTime FactorsAntigens, CDChromosomes, Human, 21-22 and YSurvival RateVincristineLeukemia, Mast-CellCell SurvivalClone CellsNuclear ProteinsNeoplasms, Second PrimaryReceptors, OSM-LIFReverse Transcriptase Polymerase Chain ReactionRadiation Leukemia VirusSialic Acid Binding Ig-like Lectin 3Leukemia, Neutrophilic, ChronicLymphocytesMice, SCIDThioguanineProtein Kinase InhibitorsProvirusesCells, CulturedAmino Acid SequenceGranulocytesSignal TransductionIn Situ Hybridization, FluorescenceAntimetabolites, AntineoplasticChromosomes, Human, Pair 8PentostatinDeltaretrovirusJurkat CellsDNA, ViralCell ProliferationTranscription, GeneticProto-Oncogene Proteins c-bcl-2Leukocyte CountDrug Screening Assays, AntitumorAntibiotics, AntineoplasticDose-Response Relationship, DrugGraft vs Host DiseaseTransfectionAntigens, CD34Myeloproliferative DisordersCyclophosphamideLeukemia, Prolymphocytic, B-CellEtoposideBlotting, SouthernOncogenesDeltaretrovirus InfectionsAntigens, SurfaceHematopoiesisChlorambucilGene Expression Regulation, NeoplasticChromosomes, Human, Pair 17Protein-Tyrosine KinasesDrug SynergismImmunoglobulin Heavy ChainsPhenotypeChromosomes, Human, Pair 12Neoplasm TransplantationChromosome DisordersArabinonucleosidesMitoxantroneGammaretrovirusHTLV-I InfectionsCombined Modality TherapyGenes, ViralMice, Inbred StrainsCell CycleProto-Oncogene Proteins c-bcrCell Transformation, ViralGene Expression ProfilingAntigens, CD38Tumor Suppressor ProteinsAntigens, CD19Gene ExpressionHarringtoninesRNA-Directed DNA PolymeraseRetrospective StudiesTumor Stem Cell AssayTumor Virus InfectionsAntibodies, Neoplasm
ChemotherapyLymphomaLymphoblastic leukemiaCancersSymptomsAdultsBoneCellsRemissionMyeloid leukemiaMyelogenousTreatmentsCancerAffectsGeneticTypicallyAggressivePeople with chronicImmuneTypeTypesCommonDiseaseChildrenTreatment for leukemiaChild's
Chemotherapy9
Lymphoma5
  • I have an 18 yrs old son with Lymphoma/Leukemia, and I have a 2 yr old toddler that I do not sp. (mamapedia.com)
  • Sima Jeha, M.D., lead clofarabine investigator and director of developmental therapeutics in the Division of Leukemia/Lymphoma at St. Jude Children's Research Hospital in Memphis, said, 'Over the past 20 years, we've made a lot of progress in treating pediatric leukemia using older agents. (drugtopics.com)
  • Due to the ongoing COVID-19 situation, The Leukemia & Lymphoma Society has made the decision to change the 2020 Leukemia Ball from an in-person event to a virtual event. (leukemiaball.org)
  • The Ball has raised over $65 million for the National Capital Area Chapter of The Leukemia & Lymphoma Society since it began in 1988. (leukemiaball.org)
  • The mission of The Leukemia & Lymphoma Society (LLS) is: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. (leukemiaball.org)
Lymphoblastic leukemia5
Cancers2
Symptoms5
Adults4
Bone9
Cells29
Remission3
  • After remission is achieved, therapy may be given to prevent a relapse of the leukemia. (rxlist.com)
  • As previously reported , Choi Sung Won recovered from acute leukemia in February of 2017 after being diagnosed in May of 2016, and the cancer has returned after almost 4 years of remission. (allkpop.com)
  • There are currently more than 300,000 people estimated to be living with or in remission (signs of disease disappear) from leukemia in the US. (rxwiki.com)
Myeloid leukemia1
Myelogenous4
Treatments2
Cancer10
Affects1
Genetic3
  • Greaves is currently doing experiments in mice which have the first genetic damage predisposing to leukemia, testing a cocktail of harmless bacteria to prime their immune systems to see if it can ultimately stop them from going on to develop leukemia. (forbes.com)
  • Occasionally there might be a genetic predisposition to developing leukemia, but the susceptibility is unknown. (choc.org)
  • While the cause of leukemia is still unknown, scientists think it may be due to a combination of genetic and environmental factors. (bannerhealth.com)
Typically1
Aggressive1
People with chronic1
  • Some people with chronic leukemia may be candidates for stem cell transplantation, which does offer a chance for cure. (rxlist.com)
Immune1
Type4
Types2
  • A prominent scientist in the UK has an explanation for the development of some types of childhood leukemia and claims it may be one day be preventable. (forbes.com)
  • The new review discusses how exposure to microbes is in some ways paradoxical, with infection likely to be the cause of the second hit but lack of exposure to some types of microbes in the first year of life, perhaps partly responsible for childhood leukemia. (forbes.com)
Common1
Disease1
Children4
Treatment for leukemia2
Child's1
Leukemia Treatments
Leukemia Treatments (news-medical.net)
Preventing Childhood Leukemia May Eventually Be Possible. As A Survivor Myself, I'm Hopeful
Preventing Childhood Leukemia May Eventually Be Possible. As A Survivor Myself, I'm Hopeful (forbes.com)
Leukemia & Lymphoma Society - YouTube
Leukemia & Lymphoma Society - YouTube (youtube.com/user/LeukemiaLymphomaSoc/)
2008 Leukemia Cup Regatta - YouTube
2008 Leukemia Cup Regatta - YouTube (youtube.com)
Cephalon Leukemia Drug Receives FDA Approval - WSJ
Cephalon Leukemia Drug Receives FDA Approval - WSJ (wsj.com)
Chronic leukemia (video) | Leukemia | Khan Academy
Chronic leukemia (video) | Leukemia | Khan Academy (khanacademy.org)
3-Year-Old Oklahoma Girl Fights Back After Diagnosed with Leukemia
3-Year-Old Oklahoma Girl Fights Back After Diagnosed with Leukemia (news.yahoo.com)
Misguided Transcriptional Elongation Causes Mixed Lineage Leukemia
Misguided Transcriptional Elongation Causes Mixed Lineage Leukemia (journals.plos.org)
Radio host Stuntman Stu announces he has leukemia | Ottawa Citizen
Radio host Stuntman Stu announces he has leukemia | Ottawa Citizen (ottawacitizen.com)
Johnny Sawyer Dyer in remission from leukemia gets grand homecoming
Johnny Sawyer Dyer in remission from leukemia gets grand homecoming (knoxnews.com)
Pregnant teen dies after abortion ban delays her chemo treatment for leukemia - CNN
Pregnant teen dies after abortion ban delays her chemo treatment for leukemia - CNN (edition.cnn.com)
Football star's final play: Donating bone marrow to mom with leukemia
Football star's final play: Donating bone marrow to mom with leukemia (app.com)
SoCal Boy With Leukemia Finally Visits Legoland - NBC 7 San Diego
SoCal Boy With Leukemia Finally Visits Legoland - NBC 7 San Diego (nbcsandiego.com)
Boston Marathon: Runner raised $10K for Red Bank student with leukemia
Boston Marathon: Runner raised $10K for Red Bank student with leukemia (app.com)
Louisville rolls in exhibition; St. X student battling leukemia steals show | Lexington Herald Leader
Louisville rolls in exhibition; St. X student battling leukemia steals show | Lexington Herald Leader (kentucky.com)
Leukemia survivor pays it forward with Swab the World campaign | Montreal Gazette
Leukemia survivor pays it forward with Swab the World campaign | Montreal Gazette (montrealgazette.com)
On borrowed time: new clinical trial for children with recurring leukemia | KOMO
On borrowed time: new clinical trial for children with recurring leukemia | KOMO (komonews.com)
Betegseg - leukemia - hir3.hu
Betegseg - leukemia - hir3.hu (hir3.hu)
ACUTE LEUKEMIA WITHOUT MAJOR O.R. PROCEDURES WITH CC - DRG Code 835
ACUTE LEUKEMIA WITHOUT MAJOR O.R. PROCEDURES WITH CC - DRG Code 835 (aapc.com)
Indians' Carlos Carrasco Has Leukemia
Indians' Carlos Carrasco Has Leukemia (deadspin.com)
Lumber Liquidators CEO Diagnosed With Leukemia, Will Continue to Work | Fortune
Lumber Liquidators CEO Diagnosed With Leukemia, Will Continue to Work | Fortune (fortune.com)
PLOS ONE: Leukemia Gene Atlas - A Public Platform for Integrative Exploration of Genome-Wide Molecular Data
PLOS ONE: Leukemia Gene Atlas - A Public Platform for Integrative Exploration of Genome-Wide Molecular Data (journals.plos.org)
Acute Myeloid Leukemia Market | Global Forecast Report, 2018-2028
Acute Myeloid Leukemia Market | Global Forecast Report, 2018-2028 (visiongain.com)
Batang nagka-leukemia, tuluyan nang gumaling at balik-eskuwela na | Video | GMA News Online
Batang nagka-leukemia, tuluyan nang gumaling at balik-eskuwela na | Video | GMA News Online (gmanetwork.com)
Blood cancer (Leukemia, Lymphoma, Myeloma) | Novant Health
Blood cancer (Leukemia, Lymphoma, Myeloma) | Novant Health (novanthealth.org)
Moxetumomab Pasudotox Pivotal Data in Patients with Previously-Treated Hairy Cell Leukemia Presented at the 2018 ASCO Meeting |...
Moxetumomab Pasudotox Pivotal Data in Patients with Previously-Treated Hairy Cell Leukemia Presented at the 2018 ASCO Meeting |... (businesswire.com)
Paso Robles police recover, refill stolen donation jar for young leukemia patient | The Tribune
Paso Robles police recover, refill stolen donation jar for young leukemia patient | The Tribune (sanluisobispo.com)
Pfizer Pulls Leukemia Treatment | Pharmaceutical Executive
Pfizer Pulls Leukemia Treatment | Pharmaceutical Executive (pharmexec.com)
Wikiwix » commons.wikimedia.org - Leukemia cells
Wikiwix » commons.wikimedia.org - Leukemia cells (wikiwix.com)
Practioner's Essences - Leukemia - Aroma Health Texas
Practioner's Essences - "Leukemia" - Aroma Health Texas (aromahealthtexas.com)
Ivan Garcia-Burgos, Acute Lymphoblastic Leukemia survivor, is Paying it Forward | City of Hope Breakthroughs
Ivan Garcia-Burgos, Acute Lymphoblastic Leukemia survivor, is Paying it Forward | City of Hope Breakthroughs (cityofhope.org)
Solanum lyratum Extracts Induce Extrinsic and Intrinsic Pathways of Apoptosis in WEHI-3 Murine Leukemia Cells and Inhibit...
Solanum lyratum Extracts Induce Extrinsic and Intrinsic Pathways of Apoptosis in WEHI-3 Murine Leukemia Cells and Inhibit... (hindawi.com)
Alex's Place - Update on Alex's Fight Against Leukemia
Alex's Place - Update on Alex's Fight Against Leukemia (alexscoupons.com)
रक्ताचा कर्करोग झालेल्या रूग्णावर असे झाले यशस्वी उपचार | Successful treatment of bone marrow transplant in a patient with...
रक्ताचा कर्करोग झालेल्या रूग्णावर असे झाले यशस्वी उपचार | Successful treatment of bone marrow transplant in a patient with... (zeenews.india.com)
University of Birmingham student from Norfolk fundraises for the Teenage Cancer Trust after friend's Leukemia diagnosis |...
University of Birmingham student from Norfolk fundraises for the Teenage Cancer Trust after friend's Leukemia diagnosis |... (edp24.co.uk)